Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
55 "Inflammatory bowel diseases"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
IBD/ Endoscopy
Adequacy of sigmoidoscopy as compared to colonoscopy for assessment of disease activity in patients of ulcerative colitis: a prospective study
Sameet Tariq Patel, Anuraag Jena, Sanjay Chandnani, Shubham Jain, Pankaj Nawghare, Saurabh Bansal, Harsh Gandhi, Rishikesh Malokar, Jay Chudasama, Prasanta Debnath, Seemily Kahmei, Rima Kamat, Sangeeta Kini, Qais Q Contractor, Pravin M Rathi
Intest Res 2024;22(3):310-318.   Published online May 16, 2024
DOI: https://doi.org/10.5217/ir.2023.00174
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Patients of ulcerative colitis (UC) on follow-up are routinely evaluated by sigmoidoscopy. There is no prospective literature to support this practice. We assessed agreement between sigmoidoscopy and colonoscopy prospectively in patients with disease extent beyond the sigmoid colon.
Methods
We conducted a prospective observational study at a tertiary care institute for agreement between sigmoidoscopy and colonoscopy. We assessed endoscopic activity using the Mayo Endoscopic Score (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and histological activity using the Nancy Index (NI), Robarts Histopathology Index (RHI), and Simplified Geboes Score (SGS).
Results
Sigmoidoscopy showed a strong agreement with colonoscopy for MES and UCEIS with a kappa (κ) of 0.96 and 0.94 respectively. The misclassification rate for MES and UCEIS was 3% and 5% respectively. Sigmoidoscopy showed perfect agreement (κ = 1.00) with colonoscopy for assessment of the presence of endoscopic activity in the colon using MES ≥ 1 as activity criteria and strong agreement (κ = 0.93) using MES > 1 as activity criteria. Sigmoidoscopy showed strong agreement with colonoscopy for assessment of the presence of endoscopic activity using UCEIS (κ = 0.92). Strong agreement was observed between sigmoidoscopy and colonoscopy using NI (κ = 0.86), RHI (κ = 1.00), and SGS (κ = 0.92) for the detection of histological activity. The misclassification rate for the detection of histological activity was 2%, 0%, and 1% for NI, RHI, and SGS respectively.
Conclusions
Sigmoidoscopy showed strong agreement with colonoscopy for endoscopic and histologic disease activity. Sigmoidoscopy is adequate for assessment of disease activity in patients with UC during follow-up evaluation.
  • 1,708 View
  • 121 Download
Close layer
Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling study
Danny Con, Peter De Cruz
Received November 17, 2023  Accepted February 15, 2024  Published online May 7, 2024  
DOI: https://doi.org/10.5217/ir.2023.00175    [Epub ahead of print]
AbstractAbstract PDFPubReaderePub
Background/Aims
Robust management algorithms are required to reduce the residual risk of colectomy in acute severe ulcerative colitis (ASUC) refractory to standard infliximab salvage therapy. The aim of this study was to evaluate the performance and benefits of alternative ASUC management strategies using simulated prediction models of varying accuracy.
Methods
This was a simulation-based modeling study using a hypothetical cohort of 5,000 steroid-refractory ASUC patients receiving standard infliximab induction. Simulated predictive models were used to risk-stratify patients and escalate treatment in patients at high risk of failing standard infliximab induction. The main outcome of interest was colectomy by 3 months.
Results
The 3-month colectomy rate in the base scenario where all 5,000 patients received standard infliximab induction was 23%. The best-performing management strategy assigned high-risk patients to sequential Janus kinase inhibitor inhibition and mediumrisk patients to accelerated infliximab induction. Using a 90% area under the curve (AUC) prediction model and optimistic treatment efficacy assumptions, this strategy reduced the 3-month colectomy rate to 8% (65% residual risk reduction). Using an 80% AUC prediction model with only modest treatment efficacy assumptions, the 3-month colectomy rate was reduced to 15% (35% residual risk reduction). Overall management strategy efficacy was highly dependent on predictive model accuracy and underlying treatment efficacy assumptions.
Conclusions
This is the first study to simulate predictive model-based management strategies in steroid-refractory ASUC and evaluate their effect on short-term colectomy rates. Future studies on predictive model development should incorporate simulation studies to better understand their expected benefit.
  • 1,005 View
  • 156 Download
Close layer
IBD
Sarcopenia is common in ulcerative colitis and correlates with disease activity
Pardhu B Neelam, Rimesh Pal, Pankaj Gupta, Anupam K Singh, Jimil Shah, Harshal S Mandavdhare, Harjeet Singh, Aravind Sekar, Sanjay K Bhadada, Usha Dutta, Vishal Sharma
Intest Res 2024;22(2):162-171.   Published online January 22, 2024
DOI: https://doi.org/10.5217/ir.2023.00090
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Association of sarcopenia with disease severity in ulcerative colitis (UC) is not clearly defined. We planned to estimate the prevalence of sarcopenia in patients with UC as per the revised definition and its relation with the disease severity.
Methods
A cross-sectional assessment of sarcopenia in patients with UC was performed. Disease activity was graded according to complete Mayo score. Hand grip strength was assessed with Jamar hand dynamometer, muscle mass using a dual energy X-ray absorptiometry scan, and physical performance with 4-m walk test. Sarcopenia was defined as a reduction of both muscle mass and strength. Severe sarcopenia was defined as reduced gait speed in presence of sarcopenia.
Results
Of 114 patients (62 males, mean age: 36.49±12.41 years), 32 (28%) were in remission, 46 (40.4%) had mild-moderate activity, and 36 (31.6%) had severe UC. Forty-three patients (37.7%) had probable sarcopenia, 25 (21.9%) had sarcopenia, and 14 (12.2%) had severe sarcopenia. Prevalence of sarcopenia was higher in active disease (2 in remission, 6 in active, and 17 in severe, P<0.001). Of 14 with severe sarcopenia, 13 had severe UC while 1 had moderate UC. On multivariate analysis, lower body mass index and higher Mayo score were associated with sarcopenia. Of 37 patients with acute severe colitis, 16 had sarcopenia. Requirement of second-line therapy was similar between patients with and without sarcopenia. On follow-up (median: 18 months), there was a non-significant higher rate of major adverse events in those with sarcopenia (47.4% vs. 33.8%, P=0.273).
Conclusions
Sarcopenia and severe sarcopenia in UC correlate with the disease activity.

Citations

Citations to this article as recorded by  
  • Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence
    Pardhu B Neelam, Alka Sharma, Vishal Sharma
    JGH Open.2024;[Epub]     CrossRef
  • Utility of SARC‐F for screening for sarcopenia in ulcerative colitis
    Pardhu B. Neelam, Vishal Sharma
    Nutrition in Clinical Practice.2024; 39(5): 1270.     CrossRef
  • Response to “Utility of SARC‐F for screening for sarcopenia in ulcerative colitis”
    Ilkay Ergenc, Chasan Ismail Basa, Alper Uzum, Sevval Sahin, Haluk Tarık Kani, Rahmi Aslan, Aslı Tufan, Özgür Kasımay, Özlen Atuğ, Yeşim Özen Alahdab
    Nutrition in Clinical Practice.2024; 39(5): 1272.     CrossRef
  • 4,040 View
  • 257 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Review
IBD
The practice of fecal microbiota transplantation in inflammatory bowel disease
Umang Arora, Saurabh Kedia, Vineet Ahuja
Intest Res 2024;22(1):44-64.   Published online November 21, 2023
DOI: https://doi.org/10.5217/ir.2023.00085
AbstractAbstract PDFPubReaderePub
Current evidence posits a central role for gut microbiota and the metabolome in the pathogenesis and progression of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) has been established as a means to manipulate this microbiome safely and sustainably. Several aspects of the technical improvement including pretreatment with antibiotics, use of frozen stool samples as well as short donor-to-recipient time are proposed to improve its response rates. Its efficacy in ulcerative colitis has been proven in clinical trials while data is emerging for Crohn’s disease. This review describes briefly the biology behind FMT, the available evidence for its use in IBD, and the host, recipient and procedural factors which determine the clinical outcomes.

Citations

Citations to this article as recorded by  
  • Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study
    Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon
    The Korean Journal of Internal Medicine.2024; 39(5): 783.     CrossRef
  • 3,579 View
  • 307 Download
  • 1 Crossref
Close layer
Original Articles
IBD
Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy
Ami Kawamoto, Kento Takenaka, Shuji Hibiya, Yoshio Kitazume, Hiromichi Shimizu, Toshimitsu Fujii, Eiko Saito, Kazuo Ohtsuka, Ryuichi Okamoto
Intest Res 2024;22(1):65-74.   Published online November 9, 2023
DOI: https://doi.org/10.5217/ir.2023.00092
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Endoscopic activity confirmed by enteroscopy is associated with poor clinical outcome in Crohn’s disease (CD). We investigated which of the existing biomarkers best reflects endoscopic activity in CD patients including the small bowel, and whether their combined use can improve accuracy.
Methods
One hundred and four consecutive patients with ileal and ileocolonic type CD who underwent balloon-assisted enteroscopy (BAE) from October 2021 to August 2022 were enrolled, with clinical and laboratory data prospectively collected and analyzed.
Results
Hemoglobin, platelet count, C-reactive protein, leucine-rich alpha-2 glycoprotein (LRG), fecal calprotectin, and fecal hemoglobin all showed significant difference in those with ulcers found on BAE. LRG and fecal calprotectin showed the highest areas under the curve (0.841 and 0.853) for detecting ulcers. LRG showed a sensitivity of 78% and specificity of 80% at a cutoff value of 13 μg/mL, whereas fecal calprotectin showed a sensitivity of 91% and specificity of 67% at a cutoff value of 151 μg/g. Dual positivity for LRG and fecal calprotectin, as well as LRG and fecal hemoglobin, both predicted ulcers with an improved specificity of 92% and 100%. A positive LRG or fecal calprotectin/hemoglobin showed an improved sensitivity of 96% and 91%. Positivity for LRG and either of the fecal biomarkers was associated with increased risk of hospitalization, surgery, and relapse.
Conclusions
The biomarkers LRG, fecal calprotectin, and fecal hemoglobin can serve as noninvasive and accurate tools for assessing activity in CD patients confirmed by BAE, especially when used in combination.

Citations

Citations to this article as recorded by  
  • Which biomarkers best reflect the degree of inflammation in Crohn’s disease?
    Jihye Park
    Intestinal Research.2024; 22(1): 1.     CrossRef
  • 3,075 View
  • 287 Download
  • 3 Web of Science
  • 1 Crossref
Close layer
IBD
Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease
Seung Bum Lee, Hyun-Ki Kim, Sang Hyuk Park, Ji-Hun Lim, Sang Hyoung Park
Intest Res 2024;22(1):75-81.   Published online November 1, 2023
DOI: https://doi.org/10.5217/ir.2023.00065
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
The achievement of endoscopic remission is an important therapeutic goal in the treatment of inflammatory bowel diseases (IBD). We aimed to evaluate the role of fecal calprotectin (FCP) and ischemia-modified albumin (IMA) as biomarkers for evaluating IBD disease activity.
Methods
A total of 48 patients with IBD (20 with ulcerative colitis and 28 with Crohn’s disease) were included in this study. FCP and serum C-reactive protein levels, erythrocyte sedimentation rate, and IMA were measured in patients with IBD and compared with endoscopic findings.
Results
Elevated FCP and serum IMA levels were significantly associated with endoscopic non-mucosal healing. The correlation between FCP and IMA was not significant. Analysis of the receiver operating characteristic curve showed that both FCP and IMA had diagnostic value in predicting non-mucosal healing. When the Ln(FCP)+IMA/10 value was calculated using both factors, the predictive value for non-mucosal healing increased; however, no significant difference was observed.
Conclusions
IMA could be a candidate serum biomarker for predicting endoscopic mucosal healing in IBD.

Citations

Citations to this article as recorded by  
  • A novel serum biomarker of endoscopic mucosal healing in inflammatory bowel disease
    Hyoun Woo Kang
    Intestinal Research.2024; 22(1): 3.     CrossRef
  • 2,211 View
  • 235 Download
  • 1 Crossref
Close layer
IBD
Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
Intest Res 2023;21(3):353-362.   Published online July 27, 2023
DOI: https://doi.org/10.5217/ir.2023.00013
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Infectious complications are major concerns when treating patients with inflammatory bowel disease (IBD). This study evaluated clinical differences across countries/regions in the management of infectious diseases in patients with IBD.
Methods
A multinational online questionnaire survey was administered to participants at the 8th meeting of the Asian Organization for Crohn’s and Colitis. The questionnaire included questions regarding surveillance, diagnosis, management, and prevention of infection in patients with IBD.
Results
A total of 384 physicians responded to the questionnaire. The majority of Korean (n=70, 63.6%) and Chinese (n=51, 51.5%) physicians preferred vancomycin to metronidazole in the treatment of Clostridium difficile infection, whereas more than half of the Japanese physicians (n=62, 66.7%) preferred metronidazole. Physicians in Korea (n=88, 80.0%) and China (n=46, 46.5%) preferred a 3-month course of isoniazid and rifampin to treat latent tuberculosis infection, whereas most physicians in Japan (n=71, 76.3%) favored a 9-month course of isoniazid. Most Korean physicians (n=89, 80.9%) recommended hepatitis B virus (HBV) vaccination in patients lacking HBV surface antigen, whereas more than half of Japanese physicians (n=53, 57.0%) did not consider vaccination.
Conclusions
Differences in the diagnosis, prevention, and management of infections in patients with IBD across countries/regions reflect different prevalence rates of infectious diseases. This survey may broaden understanding of the real-world clinical settings across Asian countries/regions and provide information for establishing practical guidelines to manage patients with IBD.

Citations

Citations to this article as recorded by  
  • The Burden of Clostridioides difficile Infection in Korea
    Seong Ran Jeon
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study
    Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon
    The Korean Journal of Internal Medicine.2024; 39(5): 783.     CrossRef
  • Assessing the associations of inflammatory bowel disease and hepatitis B virus infections with two-sample bidirectional mendelian randomization
    Ping Han, Chaohui Wang, Yan Qiu
    Critical Public Health.2024; 34(1): 1.     CrossRef
  • Diagnosis, management, and prevention of infectious complications in inflammatory bowel disease: variations among Asian countries
    Ji Eun Baek, Sung Wook Hwang
    Intestinal Research.2023; 21(3): 277.     CrossRef
  • 2,387 View
  • 91 Download
  • 2 Web of Science
  • 4 Crossref
Close layer
IBD
Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
Intest Res 2023;21(3):339-352.   Published online July 27, 2023
DOI: https://doi.org/10.5217/ir.2022.00135
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
As the characteristics of inflammatory bowel disease (IBD) differ between Asians and Westerners, it is necessary to determine adequate therapeutic strategy for Asian IBD patients. We evaluated the current treatment of IBD in Asian countries/regions using a web-based survey.
Methods
The Korean Association for the Study of Intestinal Diseases conducted a multinational web-based survey for current IBD care in Asia between September 16, 2020, and November 13, 2020.
Results
A total of 384 doctors treating IBD patients from 24 Asian countries/regions responded to the survey. Anti-tumor necrosis factor (TNF) agents, anti-integrins, and anti-interleukin-12/23 agents were available for use by 93.8%, 72.1%, and 70.1% of respondents in Asian countries/regions. Compared with a previous survey performed in 2014, an increased tendency for treatment with biologics, including anti-TNF agents, was observed. In the treatment of corticosteroid-refractory acute severe ulcerative colitis, 72.1% of respondents chose anti-TNF agents, followed by tacrolimus (11.7%). In the treatment of corticosteroid-refractory Crohn’s disease, 90.4% chose anti-TNF agents, followed by thiopurines (53.1%), anti-interleukin-12/23 agents (39.3%), and anti-integrin agents (35.7%). In the treatment of Crohn’s disease patients refractory to anti-TNF agents, the most preferred strategy was to measure serum levels of anti-TNF and anti-drug antibodies (40.9%), followed by empiric dose escalation or shortening of dosing intervals (25.3%).
Conclusions
Although there were some differences, treatment strategies for patients with IBD were mostly similar among Asian doctors. Based on the therapeutic outcomes, it is necessary to identify the most appropriate therapeutic strategy for Asian IBD patients.

Citations

Citations to this article as recorded by  
  • Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
    Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park
    Journal of Gastroenterology and Hepatology.2024; 39(3): 519.     CrossRef
  • Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
    Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
    Alimentary Pharmacology & Therapeutics.2024; 60(3): 389.     CrossRef
  • The Potential of Molecular Remission: Tissue Neutrophil Elastase Is Better Than Histological Activity for Predicting Long-Term Relapse in Patients With Ulcerative Colitis in Endoscopic Remission
    Yu Kyung Jun, Hyeon Jeong Oh, Ji Ae Lee, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
    Inflammatory Bowel Diseases.2024;[Epub]     CrossRef
  • How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
    Jihye Park
    Intestinal Research.2023; 21(3): 275.     CrossRef
  • Enrichment of Activated Fibroblasts as a Potential Biomarker for a Non-Durable Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn’s Disease
    Soo-Kyung Park, Gi-Young Lee, Sangsoo Kim, Chil-Woo Lee, Chang-Hwan Choi, Sang-Bum Kang, Tae-Oh Kim, Jaeyoung Chun, Jae-Myung Cha, Jong-Pil Im, Kwang-Sung Ahn, Seon-Young Kim, Min-Suk Kim, Chang-Kyun Lee, Dong-Il Park
    International Journal of Molecular Sciences.2023; 24(19): 14799.     CrossRef
  • 2,816 View
  • 118 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
Review
IBD
Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions
Harris A. Ahmad, James E. East, Remo Panaccione, Simon Travis, James B. Canavan, Keith Usiskin, Michael F. Byrne
Intest Res 2023;21(3):283-294.   Published online April 20, 2023
DOI: https://doi.org/10.5217/ir.2023.00020
AbstractAbstract PDFPubReaderePub
Inflammatory bowel disease encompasses Crohn’s disease and ulcerative colitis and is characterized by uncontrolled, relapsing, and remitting course of inflammation in the gastrointestinal tract. Artificial intelligence represents a new era within the field of gastroenterology, and the amount of research surrounding artificial intelligence in patients with inflammatory bowel disease is on the rise. As clinical trial outcomes and treatment targets evolve in inflammatory bowel disease, artificial intelligence may prove as a valuable tool for providing accurate, consistent, and reproducible evaluations of endoscopic appearance and histologic activity, thereby optimizing the diagnosis process and identifying disease severity. Furthermore, as the applications of artificial intelligence for inflammatory bowel disease continue to expand, they may present an ideal opportunity for improving disease management by predicting treatment response to biologic therapies and for refining the standard of care by setting the basis for future treatment personalization and cost reduction. The purpose of this review is to provide an overview of the unmet needs in the management of inflammatory bowel disease in clinical practice and how artificial intelligence tools can address these gaps to transform patient care.

Citations

Citations to this article as recorded by  
  • The Histological Detection of Ulcerative Colitis Using a No-Code Artificial Intelligence Model
    Yuichiro Hamamoto, Michihiro Kawamura, Hiroki Uchida, Kazuhiro Hiramatsu, Chiaki Katori, Hinako Asai, Shigeki Shimizu, Satoshi Egawa, Kyotaro Yoshida
    International Journal of Surgical Pathology.2024; 32(5): 890.     CrossRef
  • Could histologic healing be a new treatment target in patients with ulcerative colitis?
    Soyoung Kim, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2024; 39(1): 2.     CrossRef
  • Machine learning in the assessment and management of acute gastrointestinal bleeding
    Gaurav Bhaskar Nigam, Michael F Murphy, Simon P L Travis, Adrian J Stanley
    BMJ Medicine.2024; 3(1): e000699.     CrossRef
  • The Role of Artificial Intelligence in the Diagnosis and Treatment of Ulcerative Colitis
    Petar Uchikov, Usman Khalid, Nikola Vankov, Maria Kraeva, Krasimir Kraev, Bozhidar Hristov, Milena Sandeva, Snezhanka Dragusheva, Dzhevdet Chakarov, Petko Petrov, Bistra Dobreva-Yatseva, Ivan Novakov
    Diagnostics.2024; 14(10): 1004.     CrossRef
  • Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease
    Marietta Iacucci, Giovanni Santacroce, Irene Zammarchi, Yasuharu Maeda, Rocío Del Amor, Pablo Meseguer, Bisi Bode Kolawole, Ujwala Chaudhari, Antonio Di Sabatino, Silvio Danese, Yuichi Mori, Enrico Grisan, Valery Naranjo, Subrata Ghosh
    The Lancet Gastroenterology & Hepatology.2024; 9(8): 758.     CrossRef
  • Summary of the best evidence on self-management support schemes for patients with inflammatory bowel disease based on mobile health systems
    Chenfei Ren, Yunxian Zhou, Qian Cai, Mi Zhou
    DIGITAL HEALTH.2024;[Epub]     CrossRef
  • Deep Learning-Based Real-Time Organ Localization and Transit Time Estimation in Wireless Capsule Endoscopy
    Seung-Joo Nam, Gwiseong Moon, Jung-Hwan Park, Yoon Kim, Yun Jeong Lim, Hyun-Soo Choi
    Biomedicines.2024; 12(8): 1704.     CrossRef
  • Deep Learning Model Using Stool Pictures for Predicting Endoscopic Mucosal Inflammation in Patients With Ulcerative Colitis
    Jung Won Lee, Dongwon Woo, Kyeong Ok Kim, Eun Soo Kim, Sung Kook Kim, Hyun Seok Lee, Ben Kang, Yoo Jin Lee, Jeongseok Kim, Byung Ik Jang, Eun Young Kim, Hyeong Ho Jo, Yun Jin Chung, Hanjun Ryu, Soo-Kyung Park, Dong-Il Park, Hosang Yu, Sungmoon Jeong
    American Journal of Gastroenterology.2024;[Epub]     CrossRef
  • Potential Oral Microbial Markers for Differential Diagnosis of Crohn’s Disease and Ulcerative Colitis Using Machine Learning Models
    Sang-Bum Kang, Hyeonwoo Kim, Sangsoo Kim, Jiwon Kim, Soo-Kyung Park, Chil-Woo Lee, Kyeong Ok Kim, Geom-Seog Seo, Min Suk Kim, Jae Myung Cha, Ja Seol Koo, Dong-Il Park
    Microorganisms.2023; 11(7): 1665.     CrossRef
  • 4,957 View
  • 341 Download
  • 9 Web of Science
  • 9 Crossref
Close layer
Original Articles
IBD
Submucosal fat accumulation in Crohn’s disease: evaluation with sonography
Tomás Ripollés, María Jesús Martínez-Pérez, José María Paredes, José Vizuete, Gregorio Martin, Lidia Navarro
Intest Res 2023;21(3):385-391.   Published online March 17, 2023
DOI: https://doi.org/10.5217/ir.2022.00030
AbstractAbstract PDFPubReaderePub
Background/Aims
The study objective is to investigate the ultrasound features that allow suspecting the presence of submucosal fat deposition, called the fat halo sign (FHS), in the intestinal wall of patients with Crohn’s disease.
Methods
Computed tomography (CT) examinations over a period of 10 years were reviewed for the presence of the FHS in the bowel wall. A measurement of less than –10 Hounsfield units was regarded as indicative of fat. We included only patients who had undergone ultrasound examinations 3 months before or after CT. The study cohort group comprised 68 patients. Wall and submucosal thickness were measured on longitudinal ultrasound sections. A receiver operating characteristic curve was constructed to determine the best cutoff of ultrasound submucosal wall thickness value for predicting FHS in the bowel wall determined on CT.
Results
The FHS was present in 22 patients (31%) on CT. There were significant differences between submucosal thickness of patients with FHS and patients without FHS (4.19 mm vs. 2.41 mm). From the receiver operating characteristic curve, a threshold value of 3.1 mm of submucosal thickness had the best sensitivity and specificity to suspect FHS (95.5% and 89.1%, respectively; area under the curve, 0.962), with an odds ratio of 172. All of 16 patients with a submucosal thickness >3.9 mm had FHS.
Conclusions
FHS in patients with Crohn’s disease can be suspected on ultrasound in cases with marked thickening of the submucosa layer. In these cases, the activity of the disease should be measured by other parameters such as the color Doppler.

Citations

Citations to this article as recorded by  
  • A novel serum biomarker of endoscopic mucosal healing in inflammatory bowel disease
    Hyoun Woo Kang
    Intestinal Research.2024; 22(1): 3.     CrossRef
  • Role of Intestinal Ultrasound for IBD Care: A Practical Approach
    Joerg C. Hoffmann, Tobias Ungewitter
    Diagnostics.2024; 14(15): 1639.     CrossRef
  • 3,427 View
  • 226 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
IBD
Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India
Arshdeep Singh, Vandana Midha, Vikram Narang, Saurabh Kedia, Ramit Mahajan, Pavan Dhoble, Bhavjeet Kaur Kahlon, Ashvin Singh Dhaliwal, Ashish Tripathi, Shivam Kalra, Narender Pal Jain, Namita Bansal, Rupa Banerjee, Devendra Desai, Usha Dutta, Vineet Ahuja, Ajit Sood
Intest Res 2023;21(4):452-459.   Published online December 2, 2022
DOI: https://doi.org/10.5217/ir.2022.00087
AbstractAbstract PDFPubReaderePub
Background/Aims
Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Limited data exist on PSC in patients with IBD from India. We aimed to assess the prevalence and disease spectrum of PSC in Indian patients with IBD.
Methods
Database of IBD patients at 5 tertiary care IBD centers in India were analyzed retrospectively. Data were extracted and the prevalence of PSC-IBD was calculated.
Results
Forty-eight patients out of 12,216 patients with IBD (9,231 UC, 2,939 CD, and 46 IBD unclassified) were identified to have PSC, resulting in a prevalence of 0.39%. The UC to CD ratio was 7:1. Male sex and pancolitis (UC) or colonic CD were more commonly associated with PSC-IBD. The diagnosis of IBD preceded the diagnosis of PSC in most of the patients. Majority of the patients were symptomatic for liver disease at diagnosis. Eight patients (16.66%) developed cirrhosis, 5 patients (10.41%), all UC, developed malignancies (3 colorectal cancer [6.25%] and 2 cholangiocarcinoma [4.16%]), and 3 patients died (2 decompensated liver disease [4.16%] and 1 cholangiocarcinoma [2.08%]) on follow-up. None of the patients mandated surgical therapy for IBD.
Conclusions
Concomitant PSC in patients with IBD is uncommon in India and is associated with lower rates of development of malignancies.

Citations

Citations to this article as recorded by  
  • Frequency, spectrum and outcome of patients with primary sclerosing cholangitis among patients presenting with cholestatic jaundice
    Srikanth Kothalkar, Sayan Malakar, Piyush Mishra, Akash Mathur, Uday C. Ghoshal
    Indian Journal of Gastroenterology.2024;[Epub]     CrossRef
  • Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut–liver axis
    You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
    Experimental & Molecular Medicine.2023; 55(7): 1380.     CrossRef
  • Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
    You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
    Intestinal Research.2023; 21(4): 420.     CrossRef
  • Regional variations in the prevalence of primary sclerosing cholangitis associated with inflammatory bowel disease
    Kwang Woo Kim, Hyoun Woo Kang
    Intestinal Research.2023; 21(4): 413.     CrossRef
  • 4,361 View
  • 561 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
IBD
Inflammatory bowel disease (IBD)-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD
Arshdeep Singh, Yogesh Kumar Gupta, Ashvin Singh Dhaliwal, Bhavjeet Kaur Kahlon, Vasu Bansal, Ramit Mahajan, Varun Mehta, Dharmatma Singh, Ramandeep Kaur, Namita Bansal, Vandana Midha, Ajit Sood
Intest Res 2023;21(3):375-384.   Published online October 18, 2022
DOI: https://doi.org/10.5217/ir.2022.00037
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
The inflammatory bowel disease (IBD)-disk is a validated, visual, 10-item, self-administered questionnaire used to evaluate IBD-related disability. The present study aimed to evaluate IBD-disk in assessment of IBD daily life burden and its relation with disease activity. Methods: A cross-sectional study was conducted between June 2021 and December 2021. Patients with IBD were asked to complete the IBD-disk and a visual analogue scale of IBD daily-life burden (scored from 0–10, score >5 indicative of high burden). The internal consistency of IBD-disk, correlation with IBD daily life burden and disease activity (assessed by partial Mayo score and Harvey Bradshaw Index in patients with ulcerative colitis [UC] and Crohn’s disease [CD], respectively) and diagnostic performance of IBD-disk to detect high burden were analyzed. Results: Out of the 546 patients (mean age 40.33±13.74 years, 282 [51.6%] males) who completed the IBD-disk, 464 (84.98%) had UC and the remaining (n=82, 15.02%) had CD. A total of 311 patients (291 UC and 20 CD; 56.95%) had active disease. The mean IBD-disk total score and IBD daily life burden were 18.39±15.23 and 2.45±2.02, respectively. The IBD-disk total score correlated strongly with the IBD daily life burden (ρ=0.94, P<0.001), moderately with partial Mayo score (ρ=0.50) and weakly with Harvey Bradshaw Index (ρ=0.34). The IBD-disk total score >30 predicted high IBD daily-life burden. Conclusions: The IBD-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD and can be applied in clinical practice. (Intest Res, Published online)

Citations

Citations to this article as recorded by  
  • IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management
    P. Vega, J. M. Huguet, E. Gómez, S. Rubio, P. Suarez, M. I. Vera, J. M. Paredes, A. Hernández-Camba, R. Plaza, M. Mañosa, R. Pajares, B. Sicilia, L. Madero, S. Kolterer, C. Leitner, T. Heatta-Speicher, N. Michelena, R. Santos de Lamadrid, A. Dignass, F. G
    Digestive Diseases and Sciences.2024; 69(3): 749.     CrossRef
  • Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study
    Ferdinando D’Amico, Fernando Gomollón, Giorgos Bamias, Fernando Magro, Laura Targownik, Claudia Leitner, Tobias Heatta‐Speicher, Naiara Michelena, Stefanie Kolterer, Jennifer Lapthorn, Laura Kauffman, Axel Dignass
    United European Gastroenterology Journal.2024; 12(6): 705.     CrossRef
  • 3,645 View
  • 429 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
IBD
Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim, on behalf of Seoul National University Inflammatory Bowel Disease Research Network (SIRN)
Intest Res 2023;21(2):244-251.   Published online August 8, 2022
DOI: https://doi.org/10.5217/ir.2022.00057
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Patients with inflammatory bowel disease (IBD) are diagnosed with ankylosing spondylitis (AS) often. However, the disease course of patients with both IBD and AS is not well understood. This study aims to evaluate the effect of concomitant AS on IBD outcomes.
Methods
Among the 4,722 patients with IBD who were treated in 3 academic hospitals from 2004 to 2021, 55 were also diagnosed with AS (IBD-AS group). Based on patients’ electronic medical records, the outcomes of IBD in IBD-AS group and IBD group without AS (IBD-only group) were appraised.
Results
The proportion of patients treated with biologics or small molecule therapies was significantly higher in IBD-AS group than the proportion in IBD-only group (27.3% vs. 12.7%, P= 0.036). Patients with both ulcerative colitis and AS had a significantly higher risk of biologics or small molecule therapies than patients with only ulcerative colitis (P< 0.001). For univariable logistic regression, biologics or small molecule therapies were associated with concomitant AS (odds ratio, 4.099; 95% confidence interval, 1.863–9.021; P< 0.001) and Crohn’s disease (odds ratio, 3.552; 95% confidence interval, 1.590–7.934; P= 0.002).
Conclusions
Concomitant AS is associated with the high possibility of biologics or small molecule therapies for IBD. IBD patients who also had AS may need more careful examination and active treatment to alleviate the severity of IBD.

Citations

Citations to this article as recorded by  
  • Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
    Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • 4,439 View
  • 442 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
IBD
Clinical spectrum of elderly-onset inflammatory bowel disease in India
Yogesh Kumar Gupta, Arshdeep Singh, Vikram Narang, Vandana Midha, Ramit Mahajan, Varun Mehta, Dharmatma Singh, Namita Bansal, Madeline Vithya Barnaba Durairaj, Amit Kumar Dutta, Ajit Sood
Intest Res 2023;21(2):216-225.   Published online August 8, 2022
DOI: https://doi.org/10.5217/ir.2021.00177
AbstractAbstract PDFPubReaderePub
Background/Aims
Inflammatory bowel disease (IBD) is increasingly being recognized in elderly patients. Data on clinical spectrum of elderly-onset IBD patients is lacking from India.
Methods
A cross-sectional retrospective analysis of a prospectively maintained database of patients diagnosed with IBD was conducted at 2 centers in India. The clinical spectrum of elderly-onset IBD including demographic profile (age and sex), clinical presentation, disease characteristics (disease behavior and severity, extent of disease), and treatment were recorded and compared with adult-onset IBD.
Results
During the study period, 3,922 (3,172 ulcerative colitis [UC] and 750 Crohn’s disease [CD]) patients with IBD were recorded in the database. A total of 186 patients (4.74%; 116 males [62.36%]) had elderly-onset IBD (69.35% UC and 30.64% CD). Diarrhea, blood in stools, nocturnal frequency and pain abdomen were the commonest presentations for UC, whereas pain abdomen, weight loss and diarrhea were the most frequent symptoms in CD. For both elderly onset UC and CD, majority of the patients had moderately severe disease. Left-sided colitis was the commonest disease location in UC. Isolated ileal disease and inflammatory behavior were the most common disease location and behavior, respectively in CD. 5-Aminosalicylates were the commonest prescribed drug for both elderly onset UC and CD. Thiopurines and biologics were used infrequently. Prevalence of colorectal cancer was higher in elderly onset IBD.
Conclusions
Elderly onset IBD is not uncommon in India. Both the elderly onset UC and CD were milder, with no significant differences in disease characteristics (disease extent, location and behavior) when compared to adult-onset IBD. Colorectal cancer was more common in elderly onset IBD.

Citations

Citations to this article as recorded by  
  • Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease
    Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    European Journal of Gastroenterology & Hepatology.2024; 36(4): 445.     CrossRef
  • A prospective study of inflammatory bowel disease phenotypes in extremes of age and comparison with adults
    Nikhil Bhangale, Devendra Desai, Philip Abraham, Tarun Gupta, Pavan Dhoble, Anand Joshi
    Indian Journal of Gastroenterology.2023; 42(3): 404.     CrossRef
  • Global Epidemiology and Burden of Elderly-Onset Inflammatory Bowel Disease: A Decade in Review
    Pojsakorn Danpanichkul, Kanokphong Suparan, Suchapa Arayakarnkul, Aunchalee Jaroenlapnopparat, Natchaya Polpichai, Panisara Fangsaard, Siwanart Kongarin, Karan Srisurapanont, Banthoon Sukphutanan, Wasuwit Wanchaitanawong, Yatawee Kanjanakot, Jakrapun Pupa
    Journal of Clinical Medicine.2023; 12(15): 5142.     CrossRef
  • Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
    Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park
    Journal of Gastroenterology and Hepatology.2023;[Epub]     CrossRef
  • 4,092 View
  • 500 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
IBD
Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon
Intest Res 2022;20(3):321-328.   Published online July 20, 2021
DOI: https://doi.org/10.5217/ir.2021.00022
AbstractAbstract PDFPubReaderePub
Background/Aims
Nutritional status influences quality of life among patients with inflammatory bowel disease (IBD), although there is no clear method to evaluate nutritional status in this setting. Therefore, this study examined whether bioelectrical impedance analysis (BIA) could be used to evaluate the nutritional status of patients with IBD.
Methods
We retrospectively analyzed data from 139 Korean patients with IBD who were treated between November 2018 and November 2019. Patients were categorized as having active or inactive IBD based on the Harvey-Bradshaw index (a score of ≥5 indicates active Crohn’s disease) and the partial Mayo scoring index (a score of ≥2 indicates active ulcerative colitis). BIA results and serum nutritional markers were analyzed according to disease activity.
Results
The mean patient age was 45.11±17.71 years. The study included 47 patients with ulcerative colitis and 92 patients with Crohn’s disease. Relative to the group with active disease (n=72), the group with inactive disease (n=67) had significantly higher values for hemoglobin (P<0.001), total protein (P<0.001), and albumin (P<0.001). Furthermore, the group with inactive disease had higher BIA values for body moisture (P=0.047), muscle mass (P=0.046), skeletal muscle mass (P=0.042), body mass index (P=0.027), and mineral content (P=0.034). Moreover, the serum nutritional markers were positively correlated with the BIA results.
Conclusions
Nutritional markers evaluated using BIA were correlated with serum nutritional markers and inversely correlated with disease activity. Therefore, we suggest that BIA may be a useful tool that can help existing nutritional tests monitor the nutritional status of IBD patients.

Citations

Citations to this article as recorded by  
  • BODY FAT COMPOSITION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A COMPARATIVE STUDY BETWEEN SKINFOLDS AND ULTRASONOGRAPHY
    Isadora Sayuri Macedo TUMA, Maria Paula Carlin CAMBI, Thyago Proença de MORAES, Daniéla Oliveira MAGRO, Paulo Gustavo KOTZE
    Arquivos de Gastroenterologia.2024;[Epub]     CrossRef
  • Navigating the Intersection: Sarcopenia and Sarcopenic Obesity in Inflammatory Bowel Disease
    Valentin Calvez, Guia Becherucci, Carlo Covello, Giulia Piccirilli, Irene Mignini, Giorgio Esposto, Lucrezia Laterza, Maria Elena Ainora, Franco Scaldaferri, Antonio Gasbarrini, Maria Assunta Zocco
    Biomedicines.2024; 12(6): 1218.     CrossRef
  • Association between inflammatory bowel disease and osteoporosis in European and East Asian populations: exploring causality, mediation by nutritional status, and shared genetic architecture
    Jian Kang, Xize Wu, Yue Li, Shuangli Zhao, Shixuan Wang, Dongdong Yu
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Evaluation of Nutritional Characteristics Reveals Similar Prevalence of Malnutrition in Patients with Ulcerative Colitis and Crohn’s Disease
    Arshdeep Singh, Vandana Midha, Ramit Mahajan, Shruti Verma, Chandan Kakkar, Jasmine Grover, Dharmatma Singh, Ramandeep Kaur, Abhishek Masih, Namita Bansal, Catherine Wall, Ajit Sood
    Digestive Diseases and Sciences.2023; 68(2): 580.     CrossRef
  • Response to Ustekinumab Therapy Is Associated with an Improvement of Nutritional Status in Patients with Crohn’s Disease
    Lorenzo Bertani, Claudia D’Alessandro, Marco Fornili, Francesca Coppini, Federico Zanzi, Luca Carmisciano, Francesca Geri, Giovanni Baiano Svizzero, Emma Maria Rosi, Alice De Bernardi, Linda Ceccarelli, Maria Gloria Mumolo, Laura Baglietto, Massimo Bellin
    Journal of Clinical Medicine.2023; 12(19): 6118.     CrossRef
  • Clinical Implications of Dietary Probiotic Supplement (Associated with L-Glutamine and Biotin) in Ulcerative Colitis Patients’ Body Composition and Quality of Life
    Flavia Maria Pavel, Simona Gabriela Bungau, Delia Mirela Tit, Timea Claudia Ghitea, Ruxandra Cristina Marin, Andrei-Flavius Radu, Radu Dumitru Moleriu, Tiberia Ilias, Cristian Bustea, Cosmin Mihai Vesa
    Nutrients.2023; 15(24): 5049.     CrossRef
  • 5,229 View
  • 535 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
IBD
Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study
Kensuke Sakurai, Shigeru Furukawa, Takehiko Katsurada, Shinsuke Otagiri, Kana Yamanashi, Kazunori Nagashima, Reizo Onishi, Keiji Yagisawa, Haruto Nishimura, Takahiro Ito, Atsuo Maemoto, Naoya Sakamoto
Intest Res 2022;20(1):78-89.   Published online January 22, 2021
DOI: https://doi.org/10.5217/ir.2020.00124
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Inflammatory bowel disease (IBD) patients frequently have zinc deficiency. IBD patients with zinc deficiency have higher risks of IBD-related hospitalization, complications, and requiring surgery. This study aimed to examine the effectiveness of zinc acetate hydrate (ZAH; Nobelzin) in IBD patients with zinc deficiency.
Methods
IBD patients with zinc deficiency who received ZAH from March 2017 to April 2020 were registered in this 2-center, retrospective, observational study. Changes in serum zinc levels and disease activity (Crohn’s Disease Activity Index [CDAI]) before and after ZAH administration were analyzed.
Results
Fifty-one patients with Crohn’s disease (CD, n = 40) or ulcerative colitis (UC, n = 11) were registered. Median serum zinc level and median CDAI scores significantly improved (55.5–91.0 μg/dL, P< 0.001; 171.5–129, P< 0.001, respectively) in CD patients 4 weeks after starting ZAH administration. Similarly, median serum zinc levels and CDAI scores significantly improved (57.0–81.0 μg/dL, P< 0.001; 177–148, P= 0.012, respectively) 20 weeks after starting ZAH administration. Similar investigations were conducted in groups where no treatment change, other than ZAH administration, was implemented; significant improvements were observed in both serum zinc level and CDAI scores. Median serum zinc levels in UC patients 4 weeks after starting ZAH administration significantly improved from 63.0 to 94.0 μg/dL (P= 0.002), but no significant changes in disease activity were observed. One patient experienced side effects of abdominal discomfort and nausea.
Conclusions
ZAH administration is effective in improving zinc deficiency and may contribute to improving disease activity in IBD.

Citations

Citations to this article as recorded by  
  • Dietary Zinc Ameliorates TNBS-Induced Colitis in Mice Associated with Regulation of Th1/Th2/Th17 Balance and NF-κB/NLRP3 Signaling Pathway
    Changlin Wen, Jiayu Wang, Zhenhua Sun, Rao Zhong, Mengjie Li, Xuemei Shen, Qiaobo Ye, Kaihua Qin, Xi Peng
    Biological Trace Element Research.2024; 202(2): 659.     CrossRef
  • Nutritional Biomarkers for the Prediction of Response to Anti-TNF-α Therapy in Crohn’s Disease: New Tools for New Approaches
    Fernando Rizzello, Ilaria Maria Saracino, Paolo Gionchetti, Maria Chiara Valerii, Chiara Ricci, Veronica Imbesi, Eleonora Filippone, Irene Bellocchio, Nikolas Konstantine Dussias, Thierry Dervieux, Enzo Spisni
    Nutrients.2024; 16(2): 280.     CrossRef
  • Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer
    Yusuke Seiki, Kenji Ikezawa, Ko Watsuji, Makiko Urabe, Yugo Kai, Ryoji Takada, Takuo Yamai, Kaori Mukai, Tasuku Nakabori, Hiroyuki Uehara, Miki Ishibashi, Kazuyoshi Ohkawa
    International Journal of Clinical Oncology.2024; 29(8): 1173.     CrossRef
  • Zinc and Inflammatory Bowel Disease: From Clinical Study to Animal Experiment
    Xi Peng, Yingxiang Yang, Rao Zhong, Yuexuan Yang, Fang Yan, Na Liang, Shibin Yuan
    Biological Trace Element Research.2024;[Epub]     CrossRef
  • Role of Combination Treatment of Aspirin and Zinc in DMH-DSS-induced Colon Inflammation, Oxidative Stress and Tumour Progression in Male BALB/c Mice
    Singothu Siva Nagendra Babu, Shivani Singla, Gopabandhu Jena
    Biological Trace Element Research.2023; 201(3): 1327.     CrossRef
  • Retrospective study on the therapeutic efficacy of zinc acetate hydrate administration to patients with hypozincemia-induced dysgeusia
    Tomoaki Shintani, Kouji Ohta, Toshinori Ando, Yasutaka Hayashido, Souichi Yanamoto, Mikihito Kajiya, Hideki Shiba
    BMC Oral Health.2023;[Epub]     CrossRef
  • Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
    Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
    Nutrients.2023; 15(17): 3824.     CrossRef
  • Prevalence of Zinc Deficiency in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    Roberta Zupo, Annamaria Sila, Fabio Castellana, Roberto Bringiotti, Margherita Curlo, Giovanni De Pergola, Sara De Nucci, Gianluigi Giannelli, Mauro Mastronardi, Rodolfo Sardone
    Nutrients.2022; 14(19): 4052.     CrossRef
  • 7,276 View
  • 488 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Inflammatory Bowel Diseases
Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy
Intest Res 2021;19(4):398-407.   Published online November 20, 2020
DOI: https://doi.org/10.5217/ir.2020.00107
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Information on pediatric inflammatory bowel disease (PIBD) and very early onset IBD (VEOIBD) are sparse in India, where IBD is emerging. We aimed to evaluate characteristics of VEOIBD and later onset PIBD (LO-PIBD) in India.
Methods
We performed retrospective analysis of a large, prospectively maintained IBD registry. PIBD was divided in to VEOIBD ( < 6 years) and LO-PIBD (6–17 years). Demographic data, disease characteristics and treatment were compared between the PIBD groups and with other Asian/Western studies as well as the adult patients of the registry.
Results
Of 3,752 IBD patients, 292 (7.8%) had PIBD (0–17 years) (175 Crohn’s disease [CD], 113 ulcerative colitis [UC], 4 IBD-undifferentiated; 22 VEOIBD [7.5%], and 270 LO-PIBD [92.5%]). VEOIBD patients had more severe disease compared to LO-PIBD in both UC (P= 0.003) and CD (P< 0.001). Familial IBD was more common in VEOIBD (13.6%) compared to LO-PIBD (9.2%). Ileal disease (L1) was an independent risk factor for diagnostic delay in pediatric CD. Diagnostic delay ( > 6 months) was significantly lower in VEOIBD (40.9%) than in LO-PIBD (78.8%) (P< 0.001). Compared to other Asian and Western studies, extensive UC (72.5%) and complicated CD (stricturing/penetrating: 42.7%) were relatively more common. Perianal CD was relatively less frequent (7.4%). PIBD had a significantly higher number of complicated and ileal CD and extensive UC comparison to adult cohort of the registry.
Conclusions
VEOIBD has more aggressive phenotype than LO-PIBD. Disease appears distinct from other Asian and Western studies and adult onset disease, with more complicated CD and extensive UC.

Citations

Citations to this article as recorded by  
  • Spectrum and trend of pediatric inflammatory bowel disease: A two-decade experience from northern India
    Neelam Mohan, Shivani Deswal, Anubhuti Bhardwaj
    Indian Journal of Gastroenterology.2024; 43(1): 208.     CrossRef
  • Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
    Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
    Journal of Gastroenterology and Hepatology.2023; 38(4): 523.     CrossRef
  • Very-early-onset inflammatory bowel disease versus late-onset inflammatory bowel disease in relation to clinical phenotype: A cross-sectional study
    Hala H. Mansour, Saeed S. Seddek, Manal E. Abd E. L. Meguid, Ayman E. Eskander, Sara T. Galal
    Indian Journal of Gastroenterology.2023; 42(2): 185.     CrossRef
  • Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review
    M. Ellen Kuenzig, Stephen G. Fung, Luba Marderfeld, Joyce W.Y. Mak, Gilaad G. Kaplan, Siew C. Ng, David C. Wilson, Fiona Cameron, Paul Henderson, Paulo G. Kotze, Jasmine Bhatti, Vixey Fang, Samantha Gerber, Evelyne Guay, Supun Kotteduwa Jayawarden, Leo Ka
    Gastroenterology.2022; 162(4): 1147.     CrossRef
  • Epidemiological characteristics of Asian children with inflammatory bowel disease at diagnosis: Insights from an Asian-Pacific multi-centre registry network
    James Guoxian Huang, Yoko Kin Yoke Wong, Kee Seang Chew, Pornthep Tanpowpong, Karen Sophia Calixto Mercado, Almida Reodica, Shaman Rajindrajith, Kai-Chi Chang, Yen-Hsuan Ni, Suporn Treepongkaruna, Way-Seah Lee, Marion Margaret Aw
    World Journal of Gastroenterology.2022; 28(17): 1830.     CrossRef
  • Personalized medicine in inflammatory bowel disease: Perspectives on Asia
    Su Hyun Park, Sang Hyoung Park
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1434.     CrossRef
  • Inflammatory bowel disease in Korea: epidemiology and pathophysiology
    Jung Won Lee, Chang Soo Eun
    The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
  • Racial and Ethnic Variation in Presentation, Diagnosis, Treatment, and Outcome of Pediatric Crohn Disease: A Single Center Study
    Savini Lanka Britto, Justin Qian, Faith Dorsey Ihekweazu, Richard Kellermayer
    Journal of Pediatric Gastroenterology & Nutrition.2022; 75(3): 313.     CrossRef
  • Phenotypic Pattern of Early Versus Later-Onset Pediatric Inflammatory Bowel Disease in a Eurasian Country
    Bilge S. Akkelle, Deniz Ertem, Burcu Volkan, Engin Tutar
    Journal of Pediatric Gastroenterology & Nutrition.2022; 75(4): e61.     CrossRef
  • Clinical Features and Long-Term Outcomes of Paediatric-Onset Inflammatory Bowel Disease in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
    Sang Hyoung Park, Jong Pil Im, Hyunju Park, Seung Kyu Jeong, Ji Hyun Lee, Kyoung Hoon Rhee, Young-Ho Kim, Sung Noh Hong, Kyung Ho Kim, Seung In Seo, Jae Myung Cha, Sun Yong Park, Joo Sung Kim, Hyuk Yoon, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim, Seong O
    Journal of Crohn's and Colitis.2021;[Epub]     CrossRef
  • Predictors of Positive Video Capsule Endoscopy Findings for Chronic Unexplained Abdominal Pain: Single-Center Retrospective Study and Meta-Analysis
    Wonshik Kim, Beomjae Lee, Ahyoung Yoo, Seunghan Kim, Moonkyung Joo, Jong-Jae Park
    Diagnostics.2021; 11(11): 2123.     CrossRef
  • 8,904 View
  • 216 Download
  • 12 Web of Science
  • 11 Crossref
Close layer
Inflammatory Bowel Diseases
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, Takashi Hagiwara, Takeshi Kawaberi, Haruhiko Ogata, Toshiyuki Matsui, Mamoru Watanabe, Toshifumi Hibi
Intest Res 2021;19(4):408-418.   Published online November 20, 2020
DOI: https://doi.org/10.5217/ir.2020.00025
AbstractAbstract PDFPubReaderePub
Background/Aims
Crohn’s disease is a chronic disorder; therefore, it is essential to investigate long-term safety and efficacy of treatments. This study assessed the safety and effectiveness of adalimumab for up to 3 years in Japanese patients with Crohn’s disease in real-world settings.
Methods
This was a multicenter, single-cohort, observational study of patients with Crohn’s disease. Safety assessments included incidence of adverse drug reactions. Effectiveness assessments included clinical remission, mucosal healing, and Work Productivity and Activity Impairment (WPAI).
Results
The safety and effectiveness analysis populations comprised 389 and 310 patients, respectively. Mean (standard deviation) exposure to adalimumab in the safety analysis population was 793.4 (402.8) days, with a 58.1% retention rate. A total of 105 patients (27.0%) and 43 patients (11.1%) experienced adverse drug reactions and serious adverse drug reactions, respectively, with no patient reporting tuberculosis or hepatitis B. Infections and serious infections were reported in 37 patients (9.5%) and 17 patients (4.4%), respectively. Malignancy was reported as an adverse drug reaction in 2 patients (0.5%). Remission rate increased from 37.8% (98/259) at baseline to 73.9% (167/226) at week 4 and remained > 70% over 3 years. Proportion of patients without mucosal ulcerations increased from 2.7% (2/73) at baseline to 42.3% (11/26) between years > 2 to ≤ 3. WPAI improvement started at 4 weeks, with the overall work impairment score improving from 42.7 (n = 102) at baseline to 26.9 (n = 84) at 4 weeks.
Conclusions
Results from this study confirm the long-term safety and effectiveness of adalimumab treatment in Japanese patients with Crohn’s disease in the real-world setting.

Citations

Citations to this article as recorded by  
  • Effect of Perianal Fistula on the Quality of Life and Work Productivity of Patients with Crohn's Disease: Report of a Questionnaire Survey
    Naoto Saigusa, Takeshi Inaba
    Nippon Daicho Komonbyo Gakkai Zasshi.2024; 77(2): 89.     CrossRef
  • Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
    Seung Bum Lee, Hee Seung Hong, Chang Kyun Lee, Bo-In Lee, Sol Kim, Seong-Joon Koh, Hosun Yu, Jung-Bin Park, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2023; 38(5): 661.     CrossRef
  • Clinical features of enteric and colo-duodenal fistula in patients with Crohn’s disease
    Jun Su Lee, Sang-Bum Kang, Kwangbeom Park, Yong Sik Yoon, Chang Sik Yu, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Jong Lyul Lee, Sang Hyoung Park
    Intestinal Research.2023; 21(3): 406.     CrossRef
  • TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors
    Julie J. Hong, Edward K. Hadeler, Megan L. Mosca, Nicholas D. Brownstone, Tina Bhutani, Wilson J. Liao
    Journal of Psoriasis and Psoriatic Arthritis.2022; 7(2): 79.     CrossRef
  • Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
    Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
    Gut and Liver.2022; 16(1): 138.     CrossRef
  • Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician
    Adam Saleh, Usman Ansari, Shaadi Abughazaleh, Kerri Glassner, Bincy P Abraham
    Biologics: Targets and Therapy.2022; Volume 16: 67.     CrossRef
  • Prevention of postoperative recurrence in Crohn’s disease: the never-ending story
    Jung-Bin Park, Sang Hyoung Park
    Intestinal Research.2022; 20(3): 279.     CrossRef
  • Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
    Jihye Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2022; 37(5): 895.     CrossRef
  • Viral Hepatitis in Patients with Inflammatory Bowel Disease
    Seung Hwan Shin, Sang Hyoung Park
    The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
  • Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
    Juntao Yin, Yang Li, Yangyang Chen, Chaoyang Wang, Xiaoyong Song
    European Journal of Medical Research.2022;[Epub]     CrossRef
  • Natural history of inflammatory bowel disease: a comparison between the East and the West
    Eun Mi Song, Suk-Kyun Yang
    Intestinal Research.2022; 20(4): 418.     CrossRef
  • Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
    Jihye Park, Jae Hee Cheon
    Gut and Liver.2021; 15(5): 641.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • 5,961 View
  • 325 Download
  • 17 Web of Science
  • 13 Crossref
Close layer
Inflammatory bowel diseases
Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study
Jamilya Kaibullayeva, Aliya Ualiyeva, Ainash Oshibayeva, Anar Dushpanova, John K. Marshall
Intest Res 2020;18(4):430-437.   Published online September 29, 2020
DOI: https://doi.org/10.5217/ir.2019.00099
AbstractAbstract PDFPubReaderePub
Background/Aims
There has been a paucity of published data on the epidemiology of inflammatory bowel disease (IBD) in Central Asia and Kazakhstan. Therefore, we aimed to study IBD prevalence and patient awareness among adults in Kazakhstan.
Methods
The cross-sectional study was carried out among subjects of both sexes aged 18 years and older using IBD Alert Questionnaire (CalproQuest), single fecal calprotectin test, and endoscopy with biopsy to verify IBD from January to December 2017, across regions of Kazakhstan. All participants were included in the study after providing informed consent.
Results
Out of 115,556 subjects, there were 128 confirmed IBD cases, in which 36 Crohn’s disease (CD) and 92 ulcerative colitis (UC) cases identified. The age and sex-adjusted IBD prevalence were 113.9 (95% confidence interval [CI], 69.0–158.9) per 100,000 population. The age- and sex-adjusted prevalence for UC were 84.4 (95% CI, 44.8–123.9) and for CD were 29.5 (95% CI, 8.2–50.9) per 100,000 population.
Conclusions
This is the first report on the prevalence of IBD with a verified diagnosis in the Central Asia and could be used to better plan and allocate healthcare resources for IBD management program.

Citations

Citations to this article as recorded by  
  • Awareness of inflammatory bowel disease among the general population of Al-Baha region, Saudi Arabia
    Turki Alkully, Sarah Taishan, Wafaa Taishan, Lara Alsakka, Njood Alghamdi, Nouf Alghamdi, Mohammed Alghamdi
    Journal of Medicine and Life.2024; 17(2): 164.     CrossRef
  • Capsule endoscopy in Kazakhstan: a multicenter clinical experience
    Sang Jun Sohn, Kanat Batyrbekov, Ainura Galiakbarova, Laura Yerdaliyeva, Jamilya Kaibullayeva, Jeongwoo Ju, Haejin Lee, Yeoun Joo Lee
    Kosin Medical Journal.2024; 39(3): 179.     CrossRef
  • Systematic review with meta‐analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease
    Nishani Jayasooriya, Samantha Baillie, Jonathan Blackwell, Alex Bottle, Irene Petersen, Hanna Creese, Sonia Saxena, Richard C. Pollok
    Alimentary Pharmacology & Therapeutics.2023; 57(6): 635.     CrossRef
  • Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea
    Kwangwoo Nam, Jae Yong Lee, Yousun Ko, Kyung Won Kim, Ho-Su Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byoun, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
    Digestive Diseases and Sciences.2023; 68(6): 2165.     CrossRef
  • Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
    Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
    Intestinal Research.2023; 21(1): 137.     CrossRef
  • Obesity and novel management of inflammatory bowel disease
    Jee Hyun Kim, Chang-Myung Oh, Jun Hwan Yoo
    World Journal of Gastroenterology.2023; 29(12): 1779.     CrossRef
  • Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
    Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
    Clinical Endoscopy.2023; 56(2): 239.     CrossRef
  • Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study
    Xuejie Chen, Xin Xiang, Weitong Xia, Xindi Li, Sidan Wang, Shuyu Ye, Li Tian, Lian Zhao, Feiyan Ai, Zhaohua Shen, Kai Nie, Minzi Deng, Xiaoyan Wang
    Journal of Epidemiology and Global Health.2023; 13(4): 725.     CrossRef
  • Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy
    Kyunghwan Oh, Eun Hye Oh, Soo Min Noh, Seong Ho Park, Nayoung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
    Clinical and Translational Gastroenterology.2022; 13(1): e00442.     CrossRef
  • Changes in the Long-term Prognosis of Crohn’s Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study
    Byong Duk Ye, Sung Noh Hong, Seung In Seo, Ye-Jee Kim, Jae Myung Cha, Kyoung Hoon Rhee, Hyuk Yoon, Young-Ho Kim, Kyung Ho Kim, Sun Yong Park, Seung Kyu Jeong, Ji Hyun Lee, Hyunju Park, Joo Sung Kim, Jong Pil Im, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim,
    Gut and Liver.2022; 16(2): 216.     CrossRef
  • Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
    Sang Hyoung Park
    Intestinal Research.2022; 20(2): 159.     CrossRef
  • Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study
    Sun-Ho Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
    Intestinal Research.2022; 20(2): 203.     CrossRef
  • Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
    Ji Min Lee, Shu-Chen Wei, Kang-Moon Lee, Byong Duk Ye, Ren Mao, Hyun-Soo Kim, Soo Jung Park, Sang Hyoung Park, Eun Hye Oh, Jong Pil Im, Byung Ik Jang, Dae Bum Kim, Ken Takeuchi
    Gut and Liver.2022; 16(3): 396.     CrossRef
  • Personalized medicine in inflammatory bowel disease: Perspectives on Asia
    Su Hyun Park, Sang Hyoung Park
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1434.     CrossRef
  • Medication Adherence in Korean Patients with Inflammatory Bowel Disease and Its Associated Factors
    Kyunghwan Oh, Eun Ja Kwon, Jeong Hye Kim, Kyuwon Kim, Jae Yong Lee, Hee Seung Hong, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Jeong Yun Park, Sang Hyoung Park
    The Ewha Medical Journal.2022; 45(2): 35.     CrossRef
  • Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
    Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon
    Intestinal Research.2022; 20(3): 321.     CrossRef
  • Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
    Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2022; 37(6): 1140.     CrossRef
  • Inflammatory bowel disease in Korea: epidemiology and pathophysiology
    Jung Won Lee, Chang Soo Eun
    The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
  • Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
    Soo-Young Na, You Sun Kim
    The Korean Journal of Internal Medicine.2022; 37(5): 906.     CrossRef
  • What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
    Su Bee Park, Jin Young Yoon, Jae Myung Cha
    Gut and Liver.2022; 16(5): 676.     CrossRef
  • Natural history of inflammatory bowel disease: a comparison between the East and the West
    Eun Mi Song, Suk-Kyun Yang
    Intestinal Research.2022; 20(4): 418.     CrossRef
  • Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
    Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
    Gut and Liver.2022; 16(6): 907.     CrossRef
  • The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
    Satimai Aniwan, Priscila Santiago, Edward V. Loftus, Sang Hyoung Park
    United European Gastroenterology Journal.2022; 10(10): 1063.     CrossRef
  • Public awareness toward inflammatory bowel disease in Saudi Arabia
    Siraj Eid, Saeed Mohammad, Sulafa Noorelahi, Ali Asiri, Abdullah Taha, Ghallah Najee, Abdulkarim Aldukhail, Taif Alenezi, Rajis Aldosari
    International Journal of Medicine in Developing Countries.2021; : 929.     CrossRef
  • The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity
    Seong Kyun Kim, Ho-Su Lee, Beom-Jun Kim, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park, Masanao Nakamura
    Canadian Journal of Gastroenterology and Hepatology.2021; 2021: 1.     CrossRef
  • Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease
    Eun Soo Kim
    Gut and Liver.2021; 15(5): 637.     CrossRef
  • Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study
    Hee Seung Hong, Kyuwon Kim, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
    Therapeutic Advances in Gastroenterology.2021;[Epub]     CrossRef
  • Epidemiology and diagnosis of inflammatory bowel diseases
    Kang-Moon Lee
    Journal of the Korean Medical Association.2021; 64(9): 579.     CrossRef
  • Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
    Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study
    O. V. Knyazev, E. A. Belousova, D. I. Abdulganieva, I. V. Gubonina, J. A. Kaibullayeva, Yu. Kh. Marakhouski, E. Yu. Chashkova, M. V. Shapina, O. B. Shchukina, B. B. Gegenava, N. S. Oliferuk
    Almanac of Clinical Medicine.2021; 49(7): 443.     CrossRef
  • The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia
    Seung Wook Hong, Byong Duk Ye
    Intestinal Research.2020; 18(4): 345.     CrossRef
  • Pediatric Ulcerative Colitis in Kazakhstan: First Case Series from Central Asia and Current Clinical Management
    Dimitri Poddighe, Aigerim Telman, Ernas Tuleutayev, Aigul Ibrayeva
    Gastroenterology Insights.2020; 11(2): 27.     CrossRef
  • 5,574 View
  • 127 Download
  • 29 Web of Science
  • 32 Crossref
Close layer
Inflammatory Bowel Diseases
Yarrow oil ameliorates ulcerative colitis in mice model via regulating the NF-κB and PPAR-γ pathways
Maged E. Mohamed, Sahar A. Elsayed, Hafez R. Madkor, Heba M. Saad Eldien, Omar M. Mohafez
Intest Res 2021;19(2):194-205.   Published online August 21, 2020
DOI: https://doi.org/10.5217/ir.2020.00021
AbstractAbstract PDFPubReaderePub
Background/Aims
Ulcerative colitis (UC) is a chronic inflammatory disorder with indefinite etiology; however, environmental, genetic, immune factors and microbial agents could be implicated in its pathogenesis. UC treatment is lifelong, therefore; the potential side effects and cost of the therapy are significant. Yarrow is a promising medicinal plant with the ability to treat many disorders, owing to its bioactive compounds especially the essential oil. The main aim of this research was to investigate the therapeutic effect of the yarrow oil on colitis including the involved mechanism of action.
Methods
In 21-female C57BL/6 mice were divided into 3 groups; control group, colitis model group, and oil-treated group. Groups 2 and 3 received 5% dextran sulfate sodium (DSS) in drinking water for 9 days, and concomitantly, only group 3 was given 100 mg/kg yarrow oil. Mice were examined for their body weight, stool consistency and bleeding, and the disease activity indexes were calculated.
Results
Oral administration of yarrow oil markedly repressed the severity of UC via the reduction of the inflammatory signs and restoring colon length. The oil was able to down-regulate nuclear factor kappa light chain enhancer of activated B cells (NF-κB), up-regulate peroxisome proliferator-activated receptor gamma (PPAR-γ), and enhance transforming growth factor-β expression. The oil normalized the tumor necrosis factor-α expression, restored the normal serum level of interleukin-10 (IL-10) and reduced the serum level of IL-6.
Conclusions
Yarrow oil mitigated UC symptoms and regulated the inflammatory cytokines secretion via regulation of NF-κB and PPAR-γ pathways in the mice model, however, this recommendation requires further investigations using clinical studies to confirm the use of the oil on humans.

Citations

Citations to this article as recorded by  
  • Investigation of Yarrow Essential Oil Composition and Microencapsulation by Complex Coacervation Technology
    István Székely-Szentmiklósi, Emőke Margit Rédai, Béla Kovács, Attila-Levente Gergely, Csilla Albert, Zoltán-István Szabó, Blanka Székely-Szentmiklósi, Emese Sipos
    Applied Sciences.2024; 14(17): 7867.     CrossRef
  • Therapeutic Potential of Essential Oils Against Ulcerative Colitis: A Review
    Jinkai Li, Xiaofei Zhang, Fei Luan, Jiawei Duan, Junbo Zou, Jing Sun, Yajun Shi, Dongyan Guo, Changli Wang, Xiao Wang
    Journal of Inflammation Research.2024; Volume 17: 3527.     CrossRef
  • Pyrazole derivatives ameliorate synovial inflammation in collagen-induced arthritis mice model via targeting p38 MAPK and COX-2
    Ahlam M. Abdallah, Amany H. Abdel Naiem, Salama R. Abdelraheim, Omar M. Mohafez, Hend M. Abdelghany, Sahar A. Elsayed, Wafaey Gomaa, Heba Marey
    Naunyn-Schmiedeberg's Archives of Pharmacology.2024;[Epub]     CrossRef
  • Plant Essential Oils as Healthy Functional Ingredients of Nutraceuticals and Diet Supplements: A Review
    Riccardo Matera, Elena Lucchi, Luca Valgimigli
    Molecules.2023; 28(2): 901.     CrossRef
  • Exploring the Medicinal Potential of Achillea grandifolia in Greek Wild-Growing Populations: Characterization of Volatile Compounds, Anti-Inflammatory and Antioxidant Activities of Leaves and Inflorescences
    Olga S. Tsiftsoglou, Maria-Eleni Atskakani, Nikos Krigas, Michalis K. Stefanakis, Christos Gounaris, Dimitra Hadjipavlou-Litina, Diamanto Lazari
    Plants.2023; 12(3): 613.     CrossRef
  • The Potential of Natural Oils to Improve Inflammatory Bowel Disease
    Yaxi Zhou, Diandian Wang, Hao Duan, Shiqi Zhou, Jinhong Guo, Wenjie Yan
    Nutrients.2023; 15(11): 2606.     CrossRef
  • Variability in the volatile constituents and biological activities of Achillea millefolium L. essential oils obtained from different plant parts and by different solvents
    Hamdoon A. Mohammed, Muhamad Abd-Elraouf, Ghassan M Sulaiman, Suliman A. Almahmoud, Fatma A. Hamada, Riaz A. Khan, Mostafa M. Hegazy, Mohammed F. Abd-El-Wahab, Taha A Kedra, Ahmed Ismail
    Arabian Journal of Chemistry.2023; 16(9): 105103.     CrossRef
  • Mesosphaerum suaveolens Essential Oil Attenuates Inflammatory Response and Oxidative Stress in LPS-Stimulated RAW 264.7 Macrophages by Regulating NF-κB Signaling Pathway
    Omprakash Mohanta, Asit Ray, Sudipta Jena, Ambika Sahoo, Soumya Swarup Panda, Prabhat Kumar Das, Sanghamitra Nayak, Pratap Chandra Panda
    Molecules.2023; 28(15): 5817.     CrossRef
  • Effect of Piper nigrum essential oil in dextran sulfate sodium (DSS)-induced colitis and its potential mechanisms
    Yeye Hu, Ziliang He, Ji Zhang, Chaohua Zhang, Yanting Wang, Wei Zhang, Fenglun Zhang, Weiming Zhang, Fenglin Gu, Weicheng Hu
    Phytomedicine.2023; 119: 155024.     CrossRef
  • Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
    Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon
    Gut and Liver.2023; 17(5): 766.     CrossRef
  • Chitosan Oligosaccharides Alleviate Colitis by Regulating Intestinal Microbiota and PPARγ/SIRT1-Mediated NF-κB Pathway
    Congcong Guo, Yue Zhang, Tao Ling, Chongjie Zhao, Yanru Li, Meng Geng, Sailun Gai, Wei Qi, Xuegang Luo, Liehuan Chen, Tongcun Zhang, Nan Wang
    Marine Drugs.2022; 20(2): 96.     CrossRef
  • TMT labeled comparative proteomic analysis reveals spleen active immune responses during Clostridium perfringens type C infected piglet diarrhea
    Xiaoli Wang, Xiaoyu Huang, Qiaoli Yang, Zunqiang Yan, Pengfei Wang, Xiaoli Gao, Ruirui Luo, Shuangbao Gun
    PeerJ.2022; 10: e13006.     CrossRef
  • Exploring compounds to be used as cosmetic agents that activate peroxisome proliferator‐activated receptor alpha
    Keisuke Tachibana, Syohei Fukuda, Jun Fukushima, Kenji Ishimoto, Masahiro Sakata, Yasutomo Nishimori, Takefumi Doi
    International Journal of Cosmetic Science.2022; 44(2): 189.     CrossRef
  • Prevention of Ulcerative Colitis in Mice by Sweet Tea (Lithocarpus litseifolius) via the Regulation of Gut Microbiota and Butyric-Acid-Mediated Anti-Inflammatory Signaling
    Xiao-Qin He, Dan Liu, Hong-Yan Liu, Ding-Tao Wu, Hua-Bin Li, Xin-Shang Zhang, Ren-You Gan
    Nutrients.2022; 14(11): 2208.     CrossRef
  • In Vivo Immune Study of Achillea Fragrantissima Extract Versus Echinaid and Endoxan in Wistar Rats
    Raghad Mohammad Alhomaid, Yousef Mesfer Alharbi, Reham Mohammad Algheshairy, Mona Sulaiman Almujaydil, Hend Faisal Alharbi, Hoda Ali Ali
    Current Research in Nutrition and Food Science Journal.2022; 10(2): 733.     CrossRef
  • Achillea millefolium Essential Oil Mitigates Peptic Ulcer in Rats through Nrf2/HO-1 Pathway
    Manar K. Alomair, Lama S. Alabduladheem, Marwah A. Almajed, Amjad A. Alobaid, Essraa A. R. Alkhalifah, Nancy S. Younis, Maged E. Mohamed
    Molecules.2022; 27(22): 7908.     CrossRef
  • Validation of the Anti-Inflammatory Effect of Tenebrio Molitor Larva Oil in a Colitis Mouse Model
    B. M. Park, J. Lee, Bock Gie Jung, Bong Joo Lee
    Folia Biologica.2022; 68(2): 50.     CrossRef
  • Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats
    Bolin Li, Pengli Du, Yao Du, Danyang Zhao, Yanru Cai, Qian Yang, Zijing Guo
    Life Sciences.2021; 269: 119008.     CrossRef
  • 7,952 View
  • 186 Download
  • 20 Web of Science
  • 18 Crossref
Close layer
Reviews
Inflammatory bowel diseases
Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases
Jung Min Kim, Jae Hee Cheon
Intest Res 2020;18(3):249-264.   Published online April 18, 2020
DOI: https://doi.org/10.5217/ir.2019.00128
AbstractAbstract PDFPubReaderePub
A considerable number of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), which can present either before or after IBD diagnosis. Unraveling the pathogenic pathways of EIMs in IBD is challenging because of the lack of reliable criteria for diagnosis and difficulty in distinguishing EIMs from external pathologies caused by drugs or other etiologies. Optimizing treatment can also be difficult. Early diagnosis and management of EIM revolve around multidisciplinary teams, and they should have the resources necessary to make and implement appropriate decisions. In addition, specialists of the affected organs should be trained in IBD treatment. Furthermore, patient awareness regarding the extraintestinal symptoms of IBD is of paramount importance for improving patient understanding of disease and health outcomes. Herein, we review the pathogenesis and clinical perspectives of EIMs in IBD.

Citations

Citations to this article as recorded by  
  • Pomegranate seed oil mitigates liver and kidney damage in an experimental colitis model: Modulation of NF-κB activation and apoptosis
    Açelya Gül Koyuncu, Alev Cumbul, Elvan Yilmaz Akyüz, Müge Kopuz Alvarez Noval
    Prostaglandins & Other Lipid Mediators.2024; 171: 106804.     CrossRef
  • Screening of silent inflammatory bowel disease in seronegative spondyloarthritis patients: Fecal calprotectin, ileo-colonoscopy and histopathology assessment
    Shaimaa Badran, Andrew Saweres, Hadeel GamalEldeen, Mohamed B. Hashem, Dalia Abdel-kareem, Fatma H. Abdelraouf, Wafaa Gaber, Tamer Elbaz
    The Egyptian Rheumatologist.2024; 46(1): 6.     CrossRef
  • Leaky gut, circulating immune complexes, arthralgia, and arthritis in IBD: coincidence or inevitability?
    Xi-ya Jin, Dan-dan Li, Wei Quan, Yang Chao, Bin Zhang
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Effect of ustekinumab on extraintestinal manifestations in patients with Crohn’s disease or ulcerative colitis
    D. I. Abdulganieva, D. D. Mukhametova
    Meditsinskiy sovet = Medical Council.2024; (8): 135.     CrossRef
  • Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment
    Ilaria Faggiani, Jacopo Fanizza, Ferdinando D’Amico, Mariangela Allocca, Alessandra Zilli, Tommaso Lorenzo Parigi, Alberto Barchi, Silvio Danese, Federica Furfaro
    Biomedicines.2024; 12(8): 1839.     CrossRef
  • Long‐term clinical outcomes of intestinal Behçet's disease: A 30‐year cohort study at a tertiary hospital in South Korea
    Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon
    Journal of Gastroenterology and Hepatology.2023; 38(3): 386.     CrossRef
  • Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study
    Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park
    Intestinal Research.2023; 21(2): 252.     CrossRef
  • The Oral-Gut Axis: Periodontal Diseases and Gastrointestinal Disorders
    Gretchen A Lam, Hala Albarrak, Cassidy J McColl, Alaina Pizarro, Harsha Sanaka, Adrian Gomez-Nguyen, Fabio Cominelli, Andre Paes Batista da Silva
    Inflammatory Bowel Diseases.2023; 29(7): 1153.     CrossRef
  • Risk Factors for Surgery in Patients with Intestinal Behçet’s Disease During Anti-Tumor Necrosis Factor-Alpha Therapy
    So Jung Han, Eun Ae Kang, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    Yonsei Medical Journal.2023; 64(2): 111.     CrossRef
  • Are the risks of colorectal cancer and biliary cancer really increased if patients with ulcerative colitis have primary sclerosing cholangitis?
    Jung Wook Lee, Won Moon
    Intestinal Research.2023; 21(2): 171.     CrossRef
  • The Relationship Between Rosacea and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    Yu Kyung Jun, Da-Ae Yu, Yoo Min Han, Soo Ran Lee, Seong-Joon Koh, Hyunsun Park
    Dermatology and Therapy.2023; 13(7): 1465.     CrossRef
  • Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
    You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
    Intestinal Research.2023; 21(4): 420.     CrossRef
  • Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
    Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon
    Gut and Liver.2023; 17(5): 766.     CrossRef
  • Regional variations in the prevalence of primary sclerosing cholangitis associated with inflammatory bowel disease
    Kwang Woo Kim, Hyoun Woo Kang
    Intestinal Research.2023; 21(4): 413.     CrossRef
  • Downregulation of Heat Shock Protein 72 Contributes to Fibrostenosis in Crohn’s Disease
    Seung Won Kim, Jae-Young Lee, Han Cheol Lee, Jae Bum Ahn, Ji Hyung Kim, I Seul Park, Jae Hee Cheon, Duk Hwan Kim
    Gut and Liver.2023; 17(6): 905.     CrossRef
  • Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
    Jongwook Yu, Sung Jae Shin, Yune-Jung Park, Hyung Wook Kim, Bo-In Lee, Byong Duk Ye, Geun-Tae Kim, Sung Kook Kim, Joo Sung Kim, Young-Ho Kim, Seonjeong Jeong, Jae Hee Cheon
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Fermented rice bran supplementation attenuates chronic colitis-associated extraintestinal manifestations in female C57BL/6N mice
    Jahidul Islam, Afifah Zahra Agista, Kouichi Watanabe, Tomonori Nochi, Hisashi Aso, Yusuke Ohsaki, Takuya Koseki, Michio Komai, Hitoshi Shirakawa
    The Journal of Nutritional Biochemistry.2022; 99: 108855.     CrossRef
  • Functional Gastrointestinal Disorders in Patients with Inflammatory Bowel Disease
    Kyeong Ok Kim
    The Korean Journal of Gastroenterology.2022; 79(1): 4.     CrossRef
  • Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?
    Yong Eun Park
    Intestinal Research.2022; 20(2): 157.     CrossRef
  • A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease
    Kevin Cesa, Catherine Cunningham, Tyler Harris, Whitney Sunseri
    Cureus.2022;[Epub]     CrossRef
  • Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study
    Su Young Kim, Yeon Seo Cho, Hyun-Soo Kim, Jung Kuk Lee, Hee Man Kim, Hong Jun Park, Hyunil Kim, Jihoon Kim, Dae Ryong Kang
    Gut and Liver.2022; 16(4): 555.     CrossRef
  • Medication Adherence in Korean Patients with Inflammatory Bowel Disease and Its Associated Factors
    Kyunghwan Oh, Eun Ja Kwon, Jeong Hye Kim, Kyuwon Kim, Jae Yong Lee, Hee Seung Hong, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Jeong Yun Park, Sang Hyoung Park
    The Ewha Medical Journal.2022; 45(2): 35.     CrossRef
  • Inflammatory bowel disease in Korea: epidemiology and pathophysiology
    Jung Won Lee, Chang Soo Eun
    The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
  • Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements
    Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
    Intestinal Research.2022; 20(4): 431.     CrossRef
  • A Review of Ophthalmic Complications in Inflammatory Bowel Diseases
    Wiktoria Pytrus, Katarzyna Akutko, Tomasz Pytrus, Anna Turno-Kręcicka
    Journal of Clinical Medicine.2022; 11(24): 7457.     CrossRef
  • Atopic dermatitis does not increase the risk of inflammatory bowel disease: A nationwide cohort study
    Yu‐Ching Weng, Chao‐Kuei Juan, Hsiu J. Ho, Yi‐Ling Chang, Chun‐Ying Wu, Yi‐Ju Chen
    The Journal of Dermatology.2021; 48(2): 168.     CrossRef
  • Subclinical sacroiliitis detected by abdominopelvic computed tomography in Korean patients with Crohn’s disease
    You-Jung Ha, Hyo Jin Kim, Eugene Lee, Ji Hye Park, Young Soo Park, Yun Jong Lee, Yusuhn Kang, Hyuk Yoon
    The Korean Journal of Internal Medicine.2021; 36(4): 868.     CrossRef
  • Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet’s disease from Crohn’s disease
    Jihye Park, Daeun Jeong, Youn Wook Chung, Seunghan Han, Da Hye Kim, Jongwook Yu, Jae Hee Cheon, Ji-Hwan Ryu
    Scientific Reports.2021;[Epub]     CrossRef
  • Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management
    Gerhard Rogler, Abha Singh, Arthur Kavanaugh, David T. Rubin
    Gastroenterology.2021; 161(4): 1118.     CrossRef
  • Pancreatic Associated Manifestations in Pediatric Inflammatory Bowel Diseases
    Ugo Cucinotta, Claudio Romano, Valeria Dipasquale
    Genes.2021; 12(9): 1372.     CrossRef
  • KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement
    Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
    The Korean Journal of Gastroenterology.2021; 78(2): 105.     CrossRef
  • Epidemiology and diagnosis of inflammatory bowel diseases
    Kang-Moon Lee
    Journal of the Korean Medical Association.2021; 64(9): 579.     CrossRef
  • Current status of inflammatory bowel diseases in Korea
    Suk-Kyun Yang
    Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
  • A review of ophthalmic manifestations of inflammatory bowel disease and associated treatments
    Priya Janardhana, Saad Al-Kadhi
    Current Opinion in Ophthalmology.2021; 32(6): 549.     CrossRef
  • Etiopathogenic and Clinical Aspects in Inflammatory Bowel Disease – Literature Review
    Petronela Nicoleta Seritean Isac, Diana Popescu, Tudor Marcel Genes, Minerva Codruta Badescu, Ioana Irina Rezus, Nicoleta Dima, Ana Roxana Rusu Ganceanu, Elena Rezus, Ciprian Rezus
    Journal of Interdisciplinary Medicine.2021; 6(3): 132.     CrossRef
  • Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
    Giuseppe Cicero, Silvio Mazziotti
    Intestinal Research.2021; 19(4): 365.     CrossRef
  • Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
    Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon
    Intestinal Research.2021; 19(4): 478.     CrossRef
  • Ficus pandurata Hance Inhibits Ulcerative Colitis and Colitis‐Associated Secondary Liver Damage of Mice by Enhancing Antioxidation Activity
    Weibo Dai, Xinyi Zhan, Weijie Peng, Xin Liu, Weiwen Peng, Quanxi Mei, Xianjing Hu, Kai Wang
    Oxidative Medicine and Cellular Longevity.2021;[Epub]     CrossRef
  • Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders
    Stefano Mazza, Sara Soro, Maria Chiara Verga, Biagio Elvo, Francesca Ferretti, Fabrizio Cereatti, Andrea Drago, Roberto Grassia
    World Journal of Hepatology.2021; 13(12): 1828.     CrossRef
  • Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease
    Istvan Fedor, Eva Zold, Zsolt Barta
    Journal of Clinical Medicine.2021; 10(24): 5984.     CrossRef
  • 14,902 View
  • 443 Download
  • 41 Web of Science
  • 40 Crossref
Close layer
Inflammatory bowel diseases
Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
Sang Hyoung Park, Jae Cheol Park, Milan Lukas, Martin Kolar, Edward V. Loftus, Jr
Intest Res 2020;18(1):34-44.   Published online January 30, 2020
DOI: https://doi.org/10.5217/ir.2019.09147
AbstractAbstract PDFPubReaderePub
The inflammatory bowel diseases (IBD), which consist of Crohn’s disease and ulcerative colitis, are chronic, incurable immunemediated inflammatory disorders of the intestine. As IBD incidence continues to increase globally and its mortality is low, prevalent cases of IBD are rapidly increasing, thereby leading to a substantial increase in health care costs. Although the introduction of biologic agents for IBD management has revolutionized the armamentarium of IBD therapy, the high cost of this therapy is concerning. With the expirations of patents for existing biologic agents (originals), biosimilars with cheaper costs have been highlighted in the field of IBD. Despite concerns regarding their short- and long-term efficacy, safety, immunogenicity, and interchangeability, increasing evidence via prospective observations and phase III or IV clinical trials, which aim to prove the “biosimilarity” of biosimilars to originals, has partly confirmed their efficacy, safety, and interchangeability. Additionally, although patients and physicians are reluctant to use biosimilars, a positive budget impact has been reported owing to their use in different countries. In the near future, multiple biosimilars with lower costs, and efficacy and safety profile similar to originals, could be used to treat IBD; thus, further consideration and knowledge dissemination are warranted in this new era of biosimilars.

Citations

Citations to this article as recorded by  
  • Risk Factors of Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Jiyoung Yoon, Seung Wook Hong, Kyung-Do Han, Seung-Woo Lee, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim, Hyuk Yoon
    Gut and Liver.2024; 18(3): 489.     CrossRef
  • Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience
    Thomas W. J. Huizinga, Valeria Dipasquale, Markus Zabransky, Jens Heyn, Claudio Romano
    Expert Opinion on Biological Therapy.2024; 24(7): 615.     CrossRef
  • Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis
    Eun Soo Kim, Sung Kook Kim, Dong Il Park, Hyo Jong Kim, Yoo Jin Lee, Ja Seol Koo, Eun Sun Kim, Hyuk Yoon, Ji Hyun Lee, Ji Won Kim, Sung Jae Shin, Hyung Wook Kim, Hyun-Soo Kim, Young Sook Park, You Sun Kim, Tae Oh Kim, Jun Lee, Chang Hwan Choi, Dong Soo Ha
    Journal of Clinical Gastroenterology.2023; 57(6): 601.     CrossRef
  • Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
    Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, Byong Duk Ye, Kyeong Ok Kim, Jeong Eun Shin, Yong Sik Yoon, Hong Sub Lee, Sung Hoon Jung, Miyoung Choi, Soo-Young Na, Chang Hwan Choi, Joo Sung Kim
    Intestinal Research.2023; 21(1): 43.     CrossRef
  • Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
    Harpreet Singh, Liam Wilson, Tom Tencer, Jinender Kumar
    ClinicoEconomics and Outcomes Research.2023; Volume 15: 125.     CrossRef
  • PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients
    Christine Martinez-Vinson, Anaïs Lemoine, Yoram Bouhnik, Ben Braithwaite, Audrey Fohlen-Weill, Janet Addison
    Journal of Pediatric Gastroenterology & Nutrition.2023; 76(4): 451.     CrossRef
  • Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
    Jihye Park, Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Chang Soo Eun, Sung Hyun Kim, Sun Hee Lee, Joon Ho Lee, Stefan Schreiber
    Gut and Liver.2023; 17(3): 430.     CrossRef
  • Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals
    Quentin Jarrion, Brahim Azzouz, James Robinson, Damien Jolly, Catherine Vallet, Thierry Trenque
    Therapies.2022; 77(4): 467.     CrossRef
  • A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)
    Christopher Wynne, Christian Schwabe, Charlotte Lemech, Heimo Stroissnig, Roshan Dias, Joanna Sobierska, Eric Guenzi, Hendrik Otto, Abid Sattar, Richard Kay, Halimu N. Haliduola, Fausto Berti
    Expert Opinion on Investigational Drugs.2022; 31(9): 965.     CrossRef
  • The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)
    Enrique de-Madaria, José J Mira, Irene Carrillo, Waqqas Afif, Daphne Ang, Marina Antelo, Steven Bollipo, Antoni Castells, Prabhleen Chahal, Henriette Heinrich, Joanna K Law, Monique E van Leerdam, Sabela Lens, Rahul Pannala, San Hyoung Park, Atoosa Rabiee
    The Lancet Gastroenterology & Hepatology.2022; 7(5): 485.     CrossRef
  • Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
    Jongwook Yu, Hye Kyung Hyun, Jihye Park, Eun Ae Kang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    Gut and Liver.2022; 16(3): 414.     CrossRef
  • Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
    Jan Marsal, Manuel Barreiro-de Acosta, Irina Blumenstein, Maria Cappello, Thomas Bazin, Shaji Sebastian
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Personalized medicine in inflammatory bowel disease: Perspectives on Asia
    Su Hyun Park, Sang Hyoung Park
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1434.     CrossRef
  • Improving Global Healthcare and Reducing Costs Using Second-Generation Artificial Intelligence-Based Digital Pills: A Market Disruptor
    Yaron Ilan
    International Journal of Environmental Research and Public Health.2021; 18(2): 811.     CrossRef
  • Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects
    Kyung‐Sang Yu, In‐Jin Jang, Hyeong‐Seok Lim, Jang Hee Hong, Min‐Gul Kim, Min Kyu Park, Doo‐Yeoun Cho, Min Soo Park, Jae Yong Chung, Jong‐Lyul Ghim, SeungHwan Lee, Seok Kyu Yoon, In Sun Kwon, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Jung Bin Cha, Daniel E
    Clinical and Translational Science.2021; 14(4): 1280.     CrossRef
  • Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
    Hyo Yeop Song, Geom Seog Seo
    Journal of the Korean Medical Association.2021; 64(9): 605.     CrossRef
  • Intestinal microbiota and inflammatory bowel diseases
    Chang Soo Eun
    Journal of the Korean Medical Association.2021; 64(9): 588.     CrossRef
  • Editorial Review for: Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
    Karen Hanson
    Crohn's & Colitis 360.2021;[Epub]     CrossRef
  • Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
    Anna Pękala, Rafał Filip
    Journal of Clinical Medicine.2021; 10(22): 5311.     CrossRef
  • 6,790 View
  • 210 Download
  • 20 Web of Science
  • 19 Crossref
Close layer
Focused Review
IBD
Clinical aspects and treatments for pediatric inflammatory bowel disease
Jin Soo Moon
Intest Res 2019;17(1):17-23.   Published online January 9, 2019
DOI: https://doi.org/10.5217/ir.2018.00139
AbstractAbstract PDFPubReaderePub
The incidence of pediatric inflammatory bowel disease (IBD) is increasing worldwide, especially in the developing countries. It differs from adult disease in clinical manifestations, especially with regard to genetic predisposition in monogenic IBD. Pediatric disease also have a tendency to show more aggressive inflammation and greater extent of lesion. Newer drugs such as antitumor necrosis factor-α have been known to make a difference in treating pediatric IBD. Recent studies suggested that the patients with high risk factors might have some benefits from earlier use of biologics. To achieve treatment goals such as relieving symptoms, optimizing growth, and improving quality of life while minimizing drug toxicity, more research is needed to develop tools for risk stratification in the use of biologics for pediatric IBD.

Citations

Citations to this article as recorded by  
  • Constitutive Androstane Receptor Agonist, TCPOBOP: Maternal Exposure Impairs the Growth and Development of Female Offspring in Mice
    Shijia Pan, Yuan Guo, Wen Yu, Jia Zhang, Xiaoxiao Qiao, Letong Li, Pengfei Xu, Yonggong Zhai
    International Journal of Molecular Sciences.2023; 24(3): 2602.     CrossRef
  • Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease
    Mahmoud H. Mosli, Hajer Y. Almudaiheem, Turki AlAmeel, Shakir A. Bakkari, Othman R. Alharbi, Khalidah A. Alenzi, Amr M. Khardaly, Maha A. AlMolaiki, Bedor A. Al-Omari, Rayan G. Albarakati, Ahmed H. Al-Jedai, Omar I. Saadah, Majid A. Almadi, Badr Al-Baward
    Saudi Journal of Gastroenterology.2023; 29(Suppl 1): S1.     CrossRef
  • Lactic Acid Bacteria Isolated from Human Breast Milk Improve Colitis Induced by 2,4,6-Trinitrobenzene Sulfonic Acid by Inhibiting NF-κB Signaling in Mice
    Kyung-Joo Kim, Suhyun Kyung, Hui Jin, Minju Im, Jae-won Kim, Hyun Su Kim, Se-Eun Jang
    Journal of Microbiology and Biotechnology.2023; 33(8): 1057.     CrossRef
  • NIMBUS study protocol: a single-centre feasibility study of non-invasive monitoring with bowel ultrasound in paediatric inflammatory bowel disease
    Zachary Green, Ella Mayberry, James John Ashton, R Mark Beattie, Alison Evans, Amar Wahid, Martin Oliver Edwards
    BMJ Open.2023; 13(12): e078675.     CrossRef
  • Clinical Characteristics and Long-term Outcomes of Pediatric Ulcerative Colitis: A Single-Center Experience in Korea
    Jooyoung Jang, Sung Hee Lee, In Sook Jeong, Jinmin Cho, Hyun Jin Kim, Seak Hee Oh, Dae Yeon Kim, Ho-Su Lee, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Kyung Mo Kim
    Gut and Liver.2022; 16(2): 236.     CrossRef
  • Phenotypic Pattern of Early Versus Later-Onset Pediatric Inflammatory Bowel Disease in a Eurasian Country
    Bilge S. Akkelle, Deniz Ertem, Burcu Volkan, Engin Tutar
    Journal of Pediatric Gastroenterology & Nutrition.2022; 75(4): e61.     CrossRef
  • Xi Lei San Attenuates Dextran Sulfate Sodium-Induced Colitis in Rats and TNF-α-Stimulated Colitis in CACO2 Cells: Involvement of the NLRP3 Inflammasome and Autophagy
    Zhang Tao, Xiaoqing Zhou, Yan Zhang, Wenfeng Pu, Yi Yang, Fuxia Wei, Qian Zhou, Lin Zhang, Zhonghan Du, Ji Wu, Francesco Giudici
    Mediators of Inflammation.2021; 2021: 1.     CrossRef
  • Epidemiology and diagnosis of inflammatory bowel diseases
    Kang-Moon Lee
    Journal of the Korean Medical Association.2021; 64(9): 579.     CrossRef
  • Current status of inflammatory bowel diseases in Korea
    Suk-Kyun Yang
    Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
  • Transition Services for Pediatric Inflammatory Bowel Disease: Ready for Asian Patients Yet?
    Suk-Kyun Yang, Sang Hyoung Park, Byong Duk Ye
    Journal of Pediatric Gastroenterology & Nutrition.2021; 73(4): e107.     CrossRef
  • Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
    Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy
    Intestinal Research.2021; 19(4): 398.     CrossRef
  • Another Piece of Evidence for Early Administration of Biologics in Children with Crohn's Disease Who Start as an Inflammatory Phenotype
    Hyuk Yoon
    Gut and Liver.2021; 15(6): 791.     CrossRef
  • Risk Factors for Disease Behavior Evolution and Efficacy of Biologics in Reducing Progression in Pediatric Patients with Nonstricturing, Nonpenetrating Crohn's Disease at Diagnosis: A Single-Center Experience in Korea
    Hyun Jin Kim, Seak Hee Oh, Sung Hee Lee, Yu-Bin Kim, Dae Yeon Kim, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Kyung Mo Kim
    Gut and Liver.2021; 15(6): 851.     CrossRef
  • Repeatability of Magnetic Resonance Measurements Used for Estimating Crohn’s Disease Activity
    Ilze Apine, Ieva Pirksta, Reinis Pitura, Juris Pokrotnieks, Ieva Puķīte, Gaida Krūmiņa
    Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences..2020; 74(2): 75.     CrossRef
  • 8,513 View
  • 214 Download
  • 15 Web of Science
  • 14 Crossref
Close layer
Original Articles
IBD
Medication non-adherence in inflammatory bowel diseases is associated with disability
Jonathan Perry, Andy Chen, Viraj Kariyawasam, Glen Collins, Chee Choong, Wei Ling Teh, Nikola Mitrev, Friedbert Kohler, Rupert Wing Loong Leong
Intest Res 2018;16(4):571-578.   Published online October 10, 2018
DOI: https://doi.org/10.5217/ir.2018.00033
AbstractAbstract PDFPubReaderePub
Background/Aims
Medication non-adherence is common in inflammatory bowel diseases (IBD). The short-term consequences of non-adherence include increased disease relapse but the long-term impact upon patients in terms of daily functional impairment are less well characterized. Identifying negative outcomes, such as disability, may encourage adherence.
Methods
Consecutive ambulatory IBD subjects completed the Medication Adherence Rating Scale (MARS; non-adherence defined as ≤16), Inflammatory Bowel Diseases Disability Index (IBD-DI; disability: <3.5) and Beliefs about Medicines Questionnaire (high necessity/concerns: ≥16). The primary outcome was the association between medication non-adherence and disability. Secondary outcomes were the predictors of these outcomes.
Results
A total of 173 subjects on IBD maintenance medications were recruited (98 Crohn’s disease, 75 ulcerative colitis: median IBD-DI, –5.0; interquartile range [IQR], –14.0 to 4.0 and median MARS, 19.0; IQR, 18 to 20) of whom 24% were non-adherent. Disability correlated significantly with medication non-adherence (r=0.38, P<0.0001). Median IBD-DI for non-adherers was significantly lower than adherers (–16.0 vs. –2.0, P<0.0001). Predictors of disability included female sex (P=0.002), previous hospitalization (P=0.023), management in a referral hospital clinic (P=0.008) and medication concerns (P<0.0001). Non-adherence was independently associated with difficulty managing bowel movements (odds ratio [OR], 3.71; 95% confidence interval [CI], 1.50–9.16, P=0.005), rectal bleeding (OR, 2.69; 95% CI, 1.14–6.36; P=0.024) and arthralgia/arthritis (OR, 2.56; 95% CI, 1.11–5.92; P=0.028).
Conclusions
Medication non-adherence was associated with significantly increased disability in IBD. Female gender, higher disease severity and medication concerns were additional predictors of disability.

Citations

Citations to this article as recorded by  
  • Attitudes to medication and effects of IBD nursing service among patients with inflammatory bowel disease in Taiwan
    Chen‐Ta Yang, Tsui‐Chun Hsu, Yang‐Yuan Chen, Siou‐Ping Huang, Hsu‐Heng Yen
    Advances in Digestive Medicine.2024; 11(3): 162.     CrossRef
  • COMPLIANCE AND QUALITY OF LIFE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
    R.J. JAMOLOVA, D.K. MUKHABBATOV, D.T. RAKHMONOV, S.G. ALI-ZADE
    AVICENNA BULLETIN.2024; 26(1): 76.     CrossRef
  • High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease
    Esma H. San, Angelique Egberts, Caroline W. Th. van Dijck - van Boetzelaer, Rachel L. West, Erwin C. Vasbinder
    European Journal of Clinical Pharmacology.2024; 80(7): 1089.     CrossRef
  • MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations
    Ferdinando D'Amico, Francesca Lusetti, Laurent Peyrin-Biroulet, Silvio Danese
    Digestive and Liver Disease.2024; 56(9): 1425.     CrossRef
  • Motivational Interviewing as a Strategy to Improve Adherence in IBD Treatment: An Integrative Review Amidst COVID-19 Disruptions
    Caterina Mercuri, Maria Catone, Vincenzo Bosco, Assunta Guillari, Teresa Rea, Patrizia Doldo, Silvio Simeone
    Healthcare.2024; 12(12): 1210.     CrossRef
  • The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study
    Patrick Gagnon-Sanschagrin, Myrlene Sanon, Mikhaïl Davidson, Cynthia Willey, Sumesh Kachroo, Timothy Hoops, Dominik Naessens, Annie Guerin, Martin Cloutier
    Journal of Medical Economics.2024; 27(1): 931.     CrossRef
  • A Practical Approach to Identify Non-Adherence to Mesalamine Therapy in Inflammatory Bowel Disease
    Filippo Vernia, Giorgia Burrelli Scotti, Raffaele Borghini, Mario Muselli, Stefano Necozione, Giovanni Moretta, Lorenza Scurti, Giuseppe Donato
    Gastroenterology Insights.2024; 15(3): 754.     CrossRef
  • Use of Complementary and Alternative Therapies in People with Inflammatory Bowel Disease
    Laura Frank, Kelly Lambert
    International Journal of Environmental Research and Public Health.2024; 21(9): 1140.     CrossRef
  • A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan
    Yanfang Liu, Choo Hua Goh, Hong Qiu, Kuan-Chih Huang, Hsingwen Chung, Carine Saadoun
    Annals of Pharmacotherapy.2023; 57(9): 1053.     CrossRef
  • Development and implementation of a laboratory monitoring dashboard to reduce treatment gaps in inflammatory bowel disease
    Miranda Kozlicki, Bridget Lynch, Tony Donoho, Patrick Nichols, Autumn D Zuckerman
    American Journal of Health-System Pharmacy.2023; 80(Supplement): S55.     CrossRef
  • Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease
    Edward V. Loftus, Jenny Griffith, Ezequiel Neimark, Alexandra Song, Kori Wallace, Sujani Nannapaneni, Ji Zhou, Rachel Byrne, Kristina Kligys, Yinuo Pang, Xiaomei Liao, Jasmina Kalabic, Marla Dubinsky
    Advances in Therapy.2023; 40(5): 2311.     CrossRef
  • Development and Validation of a Remote Monitoring Tool for Assessment of Mild, Moderate, and Severe Infections in Inflammatory Bowel Disease
    Ashkan Rezazadeh Ardabili, Dirk van Esser, Dion Wintjens, Mia Cilissen, Debbie Deben, Zlatan Mujagic, Fritzi Russ, Laurents Stassen, Adriaan A Van Bodegraven, Dennis Wong, Bjorn Winkens, Daisy Jonkers, Mariëlle Romberg-Camps, Marie J Pierik
    Journal of Crohn's and Colitis.2023; 17(7): 1079.     CrossRef
  • Factors contributing to flares of ulcerative colitis in North India- a case-control study
    Vishavdeep Singh Rana, Gaurav Mahajan, Amol N. Patil, Anupam K. Singh, Vaneet Jearth, Aravind Sekar, Harjeet Singh, Atul Saroch, Usha Dutta, Vishal Sharma
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • An education‐based telehealth group improves the management and clinical outcomes of patients with inflammatory bowel disease in China (THEIM study)
    Jian Kang, Juan Su, Jing Wang, Haixia Ren, Anning Yin, Jiao Li, Qian Zhou, Yang Wang, Peng Zhu, Liping Zou, Wei Wang, Zhishun Tang, Weiguo Dong, Yijuan Ding, Ping An
    United European Gastroenterology Journal.2023; 11(10): 960.     CrossRef
  • Understanding Medication Nonadherence in Crohn’s Disease Patients: A Qualitative Evaluation
    Robert E Brady, Jessica K Salwen-Deremer, Natalie C Tunnell, Michael W Winter
    Inflammatory Bowel Diseases.2023;[Epub]     CrossRef
  • Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening
    Zohar Ben-Shatach, Tomer Ziv-Baran, Ella Fudim, Miri Yavzori, Orit Picard, Asaf Levartovsky, Limor Selinger, Batia Weiss, Uri Kopylov, Rami Eliakim, Bella Ungar
    Therapeutic Advances in Gastroenterology.2022; 15: 175628482210833.     CrossRef
  • Medication Adherence and Its Influencing Factors Among Inflammatory Bowel Disease Patients in China
    Fen Xu, Juping Tang, Zhiping Zhu, Yan Chen, Wen Hu, Sha Lu, Yunxian Zhou, Ding Lin
    International Journal of General Medicine.2022; Volume 15: 4141.     CrossRef
  • Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease Initiated on Biologic or Conventional Agents
    Dominic Pilon, Zhijie Ding, Erik Muser, Ameur M Manceur, Maude Vermette-Laforme, Marie-Hélène Lafeuille, Patrick Lefebvre
    Crohn's & Colitis 360.2022;[Epub]     CrossRef
  • Medication adherence in women with IBD of childbearing age likely associated with disease knowledge
    Robyn Laube, Christian Selinger, Rupert W. Leong
    Therapeutic Advances in Gastroenterology.2022; 15: 175628482211440.     CrossRef
  • Utility of the MARS-5 in Assessing Medication Adherence in IBD
    James K Stone, Leigh Anne Shafer, Lesley A Graff, Lisa Lix, Kelcie Witges, Laura E Targownik, Clove Haviva, Kathryn Sexton, Charles N Bernstein
    Inflammatory Bowel Diseases.2021; 27(3): 317.     CrossRef
  • Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes
    Chikako Watanabe, Masakazu Nagahori, Toshimitsu Fujii, Kaoru Yokoyama, Naoki Yoshimura, Taku Kobayashi, Hirokazu Yamagami, Kazuya Kitamura, Kagaya Takashi, Shiro Nakamura, Makoto Naganuma, Shunji Ishihara, Motohiro Esaki, Maria Yonezawa, Reiko Kunisaki, A
    Digestive Diseases and Sciences.2021; 66(2): 577.     CrossRef
  • Selected psychological predictors of medication adherence in the older adults with chronic diseases
    Magdalena Gruszczyńska, Julia Wyszomirska, Anna Daniel‐Sielańczyk, Monika Bąk‐Sosnowska
    Nursing Open.2021; 8(1): 317.     CrossRef
  • Impacto de la pandemia covid-19 en la adherencia al tratamiento en pacientes con enfermedad inflamatoria intestinal: experiencia de un centro terciario en Chile
    Rodrigo Quera, Daniela Simian, Lilian Flores, Patricio Ibáñez, Carolina Figueroa
    Gastroenterología y Hepatología.2021; 44(9): 654.     CrossRef
  • Adherence to Subcutaneous Biological Therapies in Patients with Inflammatory Rheumatic Diseases and Inflammatory Bowel Disease: A Systematic Review
    Juan C Nieto, Claudia Arajol, Loreto Carmona, Carlos Marras, Luis Cea-Calvo
    Immunotherapy.2021; 13(5): 433.     CrossRef
  • Researching Interventions to Improve Medication Adherence in Ulcerative Colitis Patients
    Mila Palma Pacheco, Flora Maria Lorenzo Fortes, Raquel Rocha dos Santos, Genoile Oliveira Santana Silva
    Journal of Coloproctology.2021; 41(01): 096.     CrossRef
  • Persistence as a Robust Indicator of Medication Adherence-Related Quality and Performance
    Enrica Menditto, Caitriona Cahir, Sara Malo, Isabel Aguilar-Palacio, Marta Almada, Elisio Costa, Anna Giardini, María Gil Peinado, Mireia Massot Mesquida, Sara Mucherino, Valentina Orlando, Carlos Luis Parra-Calderón, Enrique Pepiol Salom, Przemyslaw Kard
    International Journal of Environmental Research and Public Health.2021; 18(9): 4872.     CrossRef
  • Effect of point‐of‐care gastrointestinal ultrasound on decision‐making and management in inflammatory bowel disease
    Antony B. Friedman, Anil Asthana, Simon R. Knowles, Aphra Robbins, Peter R. Gibson
    Alimentary Pharmacology & Therapeutics.2021; 54(5): 652.     CrossRef
  • Impact of the COVID-19 pandemic on treatment adherence in patients with inflammatory bowel disease: Experience of a tertiary hospital in Chile
    Rodrigo Quera, Daniela Simian, Lilian Flores, Patricio Ibáñez, Carolina Figueroa
    Gastroenterología y Hepatología (English Edition).2021; 44(9): 654.     CrossRef
  • Adherence to treatment in patients with inflammatory bowel disease
    K. A. Andreev, A. V. Gorbenko, Yu. P. Skirdenko, N. A. Nikolaev, M. A. Livzan, G. R. Bikbavova, M. M. Fedorin
    Bulletin of Siberian Medicine.2021; 20(3): 120.     CrossRef
  • Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study
    Juan Lasa, Gustavo Correa, Claudia Fuxman, Laura Garbi, Maria Eugenia Linares, Pablo Lubrano, Astrid Rausch, Martin Toro, Martin Yantorno, Ignacio Zubiaurre, Laurent Peyrin-Biroulet, Pablo Olivera
    Gastroenterology Research and Practice.2020; 2020: 1.     CrossRef
  • Knowledge of disease and self‐management of adolescents with inflammatory bowel diseases
    Alex Krauthammer, Tal Harel, Noam Zevit, Dror S. Shouval, Raanan Shamir, Batia Weiss
    Acta Paediatrica.2020; 109(10): 2119.     CrossRef
  • The burden of cost in inflammatory bowel disease: a medical economic perspective
    Jonathan A. Beard, Benjamin H. Click
    Current Opinion in Gastroenterology.2020; 36(4): 310.     CrossRef
  • İnflamatuar Bağırsak Hastalıkları Olan Bireylerde İlaç Uyumu ve Yaşam Kalitesi
    Nazli ÖZTÜRK, Yasemin YILDIRIM
    Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi.2020; 2(3): 192.     CrossRef
  • Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus
    Marco Daperno, Alessandro Armuzzi, Silvio Danese, Walter Fries, Giuseppina Liguori, Ambrogio Orlando, Claudio Papi, Mariabeatrice Principi, Fernando Rizzello, Angelo Viscido, Paolo Gionchetti
    Gastroenterology Research and Practice.2019; 2019: 1.     CrossRef
  • The Development of a Screening Tool to Identify and Classify Nonadherence in Inflammatory Bowel Disease
    Aria Zand, Audrey Nguyen, Zack Stokes, Welmoed van Deen, Courtney Reynolds, Magdalena Dimitrova, Ariela Khandadash, Miriam Dvorsky, Jenny Sauk, Eric Esrailian, Daniel Hommes
    Crohn's & Colitis 360.2019;[Epub]     CrossRef
  • Adherence to therapy of patients with inflammatory bowel diseases
    A I Parfenov, A V Kagramanova, A F Babayan, O V Knyazev
    Terapevticheskii arkhiv.2018; 90(12): 4.     CrossRef
  • 7,946 View
  • 168 Download
  • 33 Web of Science
  • 36 Crossref
Close layer
IBD
Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study
Shiro Nakamura, Hirotsugu Imaeda, Hiroki Nishikawa, Masaki Iimuro, Minoru Matsuura, Hideo Oka, Junsuke Oku, Takako Miyazaki, Hirohito Honda, Kenji Watanabe, Hiroshi Nakase, Akira Andoh
Intest Res 2018;16(4):554-562.   Published online October 10, 2018
DOI: https://doi.org/10.5217/ir.2018.00027
AbstractAbstract PDFPubReaderePub
Background/Aims
Noninvasive objective monitoring is advantageous for optimizing treatment strategies in patients inflammatory bowel disease (IBD). Fecal calprotectin (FCP) is superior to traditional biomarkers in terms of assessing the activity in patients with IBD. However, there are the differences among several FCP assays in the dynamics of FCP. In this prospective multicenter trial, we investigated the usefulness of fecal FCP measurements in adult Japanese patients with IBD by reliable enzyme immunoassay using a monoclonal antibody.
Methods
We assessed the relationship between FCP levels and disease or endoscopic activity in patients with ulcerative colitis (UC, n=64) or Crohn’s disease (CD, n=46) compared with healthy controls (HCs, n=64).
Results
FCP levels in UC patients strongly correlated with the Disease Activity Index (rs=0.676, P<0.0001) and Mayo endoscopic subscore (MES; rs=0.677, P<0.0001). FCP levels were significantly higher even in patients with inactive UC or CD compared with HCs (P=0.0068, P<0.0001). The optimal cutoff value between MES 1 and 2 exhibited higher sensitivity (94.1%). FCP levels were significantly higher in active UC patients than in inactive patients (P<0.001), except those with proctitis. The Crohn’s Disease Activity Index tended to correlate with the FCP level (rs=0.283, P=0.0565).
Conclusions
Our testing method using a monoclonal antibody for FCP was well-validated and differentiated IBD patients from HCs. FCP may be a useful biomarker for objective assessment of disease activity in adult Japanese IBD patients, especially those with UC.

Citations

Citations to this article as recorded by  
  • Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021
    Hiroshi Nakase, Motohiro Esaki, Fumihito Hirai, Taku Kobayashi, Katsuyoshi Matsuoka, Minoru Matsuura, Makoto Naganuma, Masayuki Saruta, Kiichiro Tsuchiya, Motoi Uchino, Kenji Watanabe, Tadakazu Hisamatsu, Akira Andoh, Shigeki Bamba, Motohiro Esaki, Mikihi
    Journal of Gastroenterology.2023; 58(4): 313.     CrossRef
  • Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine
    Tomohiro Fukuda, Makoto Naganuma, Kaoru Takabayashi, Yuya Hagihara, Shun Tanemoto, Ena Nomura, Yusuke Yoshimatsu, Shinya Sugimoto, Kosaku Nanki, Shinta Mizuno, Yohei Mikami, Kayoko Fukuhara, Tomohisa Sujino, Makoto Mutaguchi, Nagamu Inoue, Haruhiko Ogata,
    Journal of Gastroenterology and Hepatology.2020; 35(11): 1878.     CrossRef
  • Clinical management for small bowel of Crohn’s disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion
    Kenji Watanabe
    Intestinal Research.2020; 18(4): 347.     CrossRef
  • 7,070 View
  • 178 Download
  • 4 Web of Science
  • 3 Crossref
Close layer
IBD
Vitamin D deficiency is associated with disease activity in patients with Crohn’s disease
Kyoung Ho Ko, You Sun Kim, Bo Kyung Lee, Jong Hyun Choi, Yong Moon Woo, Jin Young Kim, Jeong Seop Moon
Intest Res 2019;17(1):70-77.   Published online October 10, 2018
DOI: https://doi.org/10.5217/ir.2018.00022
AbstractAbstract PDFPubReaderePub
Background/Aims
Previous data suggest that vitamin D has a significant role in inflammatory bowel disease (IBD). We investigated the incidence of vitamin D deficiency in Korean patients with IBD and the correlation between serum vitamin D level and disease activity.
Methods
We retrospectively analyzed the medical records of patients with IBD whose serum vitamin D levels were checked. Deficiency of 25-hydroxyvitamin D was defined as <20 ng/mL. Disease activity was evaluated using the partial Mayo score for ulcerative colitis (≥2 defined as active disease) and Harvey-Bradshaw index for Crohn’s disease (≥4 defined as active disease).
Results
We enrolled 87 patients with IBD (ulcerative colitis [UC], 45; Crohn’s disease [CD], 42). Among them, 65.5% (57/87) were men, with a mean age of 44.9±15.1 years (range, 18–75 years). The mean duration of disease was 4.7±4.8 years (range, 0.1–17.1 years). Vitamin D deficiency was found in 73.6% (64/87) of patients with IBD. Patients with IBD (mean vitamin D level, 16.3±9.0 ng/mL) showed lower vitamin D level than the healthy control group (mean vitamin D level, 20.4±7.0 ng/mL), with no statistically significant difference (P=0.136). Disease activity was inversely correlated with vitamin D deficiency in patients with CD (P=0.007). However, no correlation was observed in patients with UC (P=0.134).
Conclusions
Approximately 75% of Korean patients with IBD showed vitamin D deficiency state. Vitamin D deficiency is associated with disease activity, particularly in patients with CD.

Citations

Citations to this article as recorded by  
  • Correlation of Socioeconomic and Environmental Factors With Incidence of Crohn Disease in Children and Adolescents: Systematic Review and Meta-Regression
    Jens Weidner, Ingmar Glauche, Ulf Manuwald, Ivana Kern, Ines Reinecke, Franziska Bathelt, Makan Amin, Fan Dong, Ulrike Rothe, Joachim Kugler
    JMIR Public Health and Surveillance.2024; 10: e48682.     CrossRef
  • Is Serum 25-Hydroxyvitamin D Level Associated with Severity of COVID-19? A Retrospective Study
    Munachimso Kizito Mbata, Mireille Hunziker, Anja Makhdoomi, Giorgia Lüthi-Corridori, Maria Boesing, Stéphanie Giezendanner, Jürgen Muser, Anne B. Leuppi-Taegtmeyer, Jörg D. Leuppi
    Journal of Clinical Medicine.2023; 12(17): 5520.     CrossRef
  • Genotype Prevalence of Lactose Deficiency, Vitamin D Deficiency, and the Vitamin D Receptor in a Chilean Inflammatory Bowel Disease Cohort: Insights from an Observational Study
    Tamara Pérez-Jeldres, M. Bustamante, Roberto Segovia-Melero, Nataly Aguilar, Fabien Magne, Gabriel Ascui, Denisse Uribe, Lorena Azócar, Cristián Hernández-Rocha, Ricardo Estela, Verónica Silva, Andrés De La Vega, Elizabeth Arriagada, Mauricio Gonzalez, Gi
    International Journal of Molecular Sciences.2023; 24(19): 14866.     CrossRef
  • The correlation between serum 25-hydroxyvitamin D level and ulcerative colitis: a systematic review and meta-analysis
    Chenyu Liu, Xin Liu, Haitao Shi, Fenrong Chen, Linlang Sun, Xin Gao, Yan Wang
    European Journal of Gastroenterology & Hepatology.2023; 35(12): 1375.     CrossRef
  • Prevalence and relevant factors of micronutrient deficiencies in hospitalized patients with inflammatory bowel disease
    Xiaojuan Li, Yedong Hu, Xiaodan Shi, Xinyan Zhu, Fei Liu
    Nutrition.2022; 99-100: 111671.     CrossRef
  • The Role of Vitamin D in Immune System and Inflammatory Bowel Disease
    Zengrong Wu, Deliang Liu, Feihong Deng
    Journal of Inflammation Research.2022; Volume 15: 3167.     CrossRef
  • Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
    Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon
    Intestinal Research.2022; 20(3): 321.     CrossRef
  • The Crosstalk between Vitamin D and Pediatric Digestive Disorders
    Cristina Oana Mărginean, Lorena Elena Meliț, Reka Borka Balas, Anca Meda Văsieșiu, Tudor Fleșeriu
    Diagnostics.2022; 12(10): 2328.     CrossRef
  • Intestinal vitamin D receptor signaling ameliorates dextran sulfate sodium‐induced colitis by suppressing necroptosis of intestinal epithelial cells
    Yongyan Shi, Xuewei Cui, Yanli Sun, Qun Zhao, Tianjing Liu
    The FASEB Journal.2020; 34(10): 13494.     CrossRef
  • Relationship Between Vitamin D Deficiency and Disease Activity in Patients with Inflammatory Bowel Disease in Ahvaz, Iran


    Esmat Rasouli, Narges Sadeghi, Abazar Parsi, Seyed Jalal Hashemi, Morteza Nayebi, Aliakbar Shayesteh
    Clinical and Experimental Gastroenterology.2020; Volume 13: 419.     CrossRef
  • Inflammatory Bowel Disease and Vitamin D
    Ki Bae Kim, Hyoung Woo Kim, Jun Su Lee, Soon Man Yoon
    The Korean Journal of Gastroenterology.2020; 76(6): 275.     CrossRef
  • Implications of the Westernized Diet in the Onset and Progression of IBD
    Fernando Rizzello, Enzo Spisni, Elisabetta Giovanardi, Veronica Imbesi, Marco Salice, Patrizia Alvisi, Maria Chiara Valerii, Paolo Gionchetti
    Nutrients.2019; 11(5): 1033.     CrossRef
  • Vitamin D deficiency associated with Crohn’s disease and ulcerative colitis: a meta-analysis of 55 observational studies
    Xi-Xi Li, Yang Liu, Jie Luo, Zhen-Dong Huang, Chao Zhang, Yan Fu
    Journal of Translational Medicine.2019;[Epub]     CrossRef
  • Vitamin D Deficiency is Associated with Increased Disease Activity in Patients with Inflammatory Bowel Disease
    Johannes Hausmann, Alica Kubesch, Mana Amiri, Natalie Filmann, Irina Blumenstein
    Journal of Clinical Medicine.2019; 8(9): 1319.     CrossRef
  • The Association of Disease Activity, BMI and Phase Angle with Vitamin D Deficiency in Patients with IBD
    Maria Chiara Mentella, Franco Scaldaferri, Marco Pizzoferrato, Antonio Gasbarrini, Giacinto Abele Donato Miggiano
    Nutrients.2019; 11(11): 2583.     CrossRef
  • 7,539 View
  • 300 Download
  • 18 Web of Science
  • 15 Crossref
Close layer
IBD
Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea
Ji Young Chang, Sung-Ae Jung, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Ki-Nam Shim
Intest Res 2018;16(4):599-608.   Published online October 10, 2018
DOI: https://doi.org/10.5217/ir.2018.00012
AbstractAbstract PDFPubReaderePub
Background/Aims
Testing for hepatitis B virus (HBV) serologic markers and appropriate vaccination are required in the management of inflammatory bowel disease (IBD) patients. We evaluated immunogenicity for HBV in IBD patients and the response to the HBV vaccination.
Methods
From May 2014 to August 2016, patients diagnosed with IBD were prospectively included and evaluated for anti-HBs antibody, anti-HBc antibody, and HBs antigen. Among the 73 patients who were confirmed with nonimmunity to HBV, 44 patients who had completed the 3-dose HBV vaccination series received a single booster vaccination, while 29 patients who had not completed the vaccinations series or were unsure of receiving the vaccination received a full vaccination series.
Results
An optimal response was obtained in 70.5% of the patients in the booster group, and 89.7% of the patients in the full vaccination group. Age younger than 26 years (odds ratio [OR], 6.01; 95% confidence interval [CI], 1.15–31.32; P=0.033) and a complete previous vaccination series (OR, 0.15; 95% CI, 0.03–0.80; P=0.026) were associated with optimal vaccine response. Previous complete vaccination series (OR, 0.11; 95% CI, 0.02–0.73; P=0.022) was the only predictive factor for lower compliance.
Conclusions
The response to the HBV vaccination was lower in patients older than 26 years and for those patients with a complete vaccination history. Since patients with a complete vaccination history also had poor compliance, serum HBV-titers should be checked more thoroughly, and a full vaccination series should be administered in cases when there is a negative response to the booster vaccination.

Citations

Citations to this article as recorded by  
  • Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study
    Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow
    Vaccines.2024; 12(4): 364.     CrossRef
  • Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease
    Anupam Kumar Singh, Anuraag Jena, Gaurav Mahajan, Ritin Mohindra, Vikas Suri, Vishal Sharma
    Alimentary Pharmacology & Therapeutics.2022; 55(8): 908.     CrossRef
  • Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study
    Anurag Mishra, Amarender Singh Puri, Sanjeev Sachdeva, Ashok Dalal
    Intestinal Research.2022; 20(4): 445.     CrossRef
  • A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency
    Elda Righi, Tolinda Gallo, Anna Maria Azzini, Fulvia Mazzaferri, Maddalena Cordioli, Mara Merighi, Evelina Tacconelli
    Infectious Diseases and Therapy.2021; 10(2): 637.     CrossRef
  • Vaccination in the Elderly and IBD
    Anthony J. Choi, Preston Atteberry, Dana J. Lukin
    Current Treatment Options in Gastroenterology.2019; 17(4): 492.     CrossRef
  • 7,664 View
  • 140 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Case Report
IBD
Enteric infections complicating ulcerative colitis
Dejan Micic, Ayal Hirsch, Namrata Setia, David T. Rubin
Intest Res 2018;16(3):489-493.   Published online July 27, 2018
DOI: https://doi.org/10.5217/ir.2018.16.3.489
AbstractAbstract PDFPubReaderePub

Enteric infections have previously been postulated to play a role in the pathogenesis of inflammatory bowel disease (IBD), however, little evidence exists in the etiologic role of specific enteric infections in the development of IBD. When encountered in the setting of IBD, enteric infections pose a clinical challenge in management given the competing treatment strategies for infectious conditions and autoimmune disorders. Here we present the case of a young male with enteric infections complicating a new diagnosis of IBD. Our patient's initial clinical presentation included diagnoses of Klebsiella oxytoca isolation and Clostridium difficile infection. Directed therapies to include withdrawal of antibiotics and fecal microbiota transplantation were performed without resolution of clinical symptoms. Given persistence of symptoms and active colitis, the patient was diagnosed with ulcerative colitis (UC), requiring treatments directed at severe UC to include cyclosporine therapy. The finding of multiple enteric infections in a newly presenting patient with IBD is an unexpected finding that has treatment implications.

Citations

Citations to this article as recorded by  
  • Echinacea purpurea Polysaccharide Ameliorates Dextran Sulfate Sodium-Induced Colitis by Restoring the Intestinal Microbiota and Inhibiting the TLR4-NF-κB Axis
    Fan-Hao Wei, Wen-Yin Xie, Pei-Sen Zhao, Wei Gao, Fei Gao
    Nutrients.2024; 16(9): 1305.     CrossRef
  • Inflammatory bowel disease complicated with rare pathogen infection
    Jia-Heng Fang, Guo-Xiong Li
    World Chinese Journal of Digestology.2023; 31(1): 8.     CrossRef
  • Usefulness of Stool Multiplex Polymerase Chain Reaction Assays in Patients with Acute Diarrhea
    Seo Hyun Kim, You Sun Kim, Seung Hyuk Kim, Won Eui Yoon, Hee Jun Myung, Jeong Seop Moon, Dong Hee Whang
    The Korean Journal of Gastroenterology.2022; 79(3): 118.     CrossRef
  • Animal unit hygienic conditions influence mouse intestinal microbiota and contribute to T-cell-mediated colitis
    Mariana Cázares-Olivera, Dominika Miroszewska, Lili Hu, Jacek Kowalski, Ulla-Marjut Jaakkola, Seppo Salminen, Bin Li, Emrah Yatkin, Zhi Chen
    Experimental Biology and Medicine.2022; 247(19): 1752.     CrossRef
  • Gut Microbiota-Mediated NLRP12 Expression Drives the Attenuation of Dextran Sulphate Sodium-Induced Ulcerative Colitis by Qingchang Wenzhong Decoction
    Zhongmei Sun, Wenjing Pei, Yi Guo, Zhibin Wang, Rui Shi, Xiaowei Chen, Xingjie Zhao, Chen Chen, Jiali Liu, Xiang Tan, Wenjing Yuan, Tangyou Mao
    Evidence-Based Complementary and Alternative Medicine.2019; 2019: 1.     CrossRef
  • Intestinal autophagy links psychosocial stress with gut microbiota to promote inflammatory bowel disease
    Shu-Ling Wang, Bo-Zong Shao, Sheng-Bing Zhao, Xin Chang, Pei Wang, Chao-Yu Miao, Zhao-Shen Li, Yu Bai
    Cell Death & Disease.2019;[Epub]     CrossRef
  • 6,561 View
  • 99 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Original Article
IBD
The association between new generation oral contraceptive pill and the development of inflammatory bowel diseases
Santosh Sanagapalli, Yanna Ko, Viraj Kariyawasam, Siew C Ng, Whitney Tang, Hithanadura Janaka de Silva, Minhu Chen, Kaichun Wu, Satimai Aniwan, Ka Kei Ng, David Ong, Qin Ouyang, Ida Hilmi, Marcellus Simadibrata, Pises Pisespongsa, Saranya Gopikrishna, Rupert W Leong
Intest Res 2018;16(3):409-415.   Published online July 27, 2018
DOI: https://doi.org/10.5217/ir.2018.16.3.409
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

To examine the association between use of oral contraceptive pills (OCPs) and the risk of developing inflammatory bowel diseases (IBD), in a modern cohort.

Methods

A prospective nested case-control study across sites in the Asia-Pacific region was conducted; involving female IBD cases and asymptomatic controls. Subjects completed a questionnaire addressing questions related to OCP use. Primary outcome was the risk of development of IBD of those exposed to OCP versus non-exposure. Secondary outcomes were development of Crohn's disease (CD) versus ulcerative colitis (UC), and whether age of first use of OCP use may be associated with risk of IBD.

Results

Three hundred and forty-eight female IBD cases (41% CD, median age: 43 years) and 590 female age-matched controls were recruited. No significant association was found between OCP use and the risk of IBD (odds ratio [OR], 1.65; 95% confidence interval, 0.77–3.13; P=0.22), CD (OR, 1.55) or UC (OR, 1.01). The lack of association persisted when results were adjusted for age and smoking. IBD cases commenced OCP use at a younger age than controls (18 years vs. 20 years, P=0.049).

Conclusions

In this large cohort of subjects from the Asia-Pacific region, we found a modest but not significantly increased risk of developing IBD amongst OCP users.

Citations

Citations to this article as recorded by  
  • Estrogen receptor actions in colitis
    Erika L. Garcia-Villatoro, Clinton D. Allred
    Essays in Biochemistry.2021; 65(6): 1003.     CrossRef
  • Sex-based differences in inflammatory bowel diseases: a review
    Sheila D. Rustgi, Maia Kayal, Shailja C. Shah
    Therapeutic Advances in Gastroenterology.2020; 13: 175628482091504.     CrossRef
  • 7,282 View
  • 103 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Review
IBD
Delineating inflammatory bowel disease through transcriptomic studies: current review of progress and evidence
Seow-Neng Chan, Eden Ngah Den Low, Raja Affendi Raja Ali, Norfilza Mohd Mokhtar
Intest Res 2018;16(3):374-383.   Published online July 27, 2018
DOI: https://doi.org/10.5217/ir.2018.16.3.374
AbstractAbstract PDFPubReaderePub

Inflammatory bowel disease (IBD), which comprises of Crohn's disease and ulcerative colitis, is an idiopathic relapsing and remitting disease in which the interplay of different environment, microbial, immunological and genetic factors that attribute to the progression of the disease. Numerous studies have been conducted in multiple aspects including clinical, endoscopy and histopathology for the diagnostics and treatment of IBD. However, the molecular mechanism underlying the aetiology and pathogenesis of IBD is still poorly understood. This review tries to critically assess the scientific evidence at the transcriptomic level as it would help in the discovery of RNA molecules in tissues or serum between the healthy and diseased or different IBD subtypes. These molecular signatures could potentially serve as a reliable diagnostic or prognostic biomarker. Researchers have also embarked on the study of transcriptome to be utilized in targeted therapy. We focus on the evaluation and discussion related to the publications reporting the different approaches and techniques used in investigating the transcriptomic changes in IBD with the intention to offer new perspectives to the landscape of the disease.

Citations

Citations to this article as recorded by  
  • Composition of the colon microbiota in the individuals with inflammatory bowel disease and colon cancer
    Ceren Acar, Sibel Kucukyildirim Celik, H. Ozgur Ozdemirel, Beril Erdem Tuncdemir, Saadet Alan, Hatice Mergen
    Folia Microbiologica.2024; 69(2): 333.     CrossRef
  • Cytokine Signatures in Inflamed Mucosa of IBD Patients: State-of-the-Art
    Milena Peruhova, Dimitrina Miteva, Maria Kokudeva, Sonya Banova, Tsvetelina Velikova
    Gastroenterology Insights.2024; 15(2): 471.     CrossRef
  • CrohnDB: A Web Database for Expression Profiling of Protein-Coding and Long Non-Coding RNA Genes in Crohn Disease
    Rebecca Distefano, Mirolyuba Ilieva, Jens Hedelund Madsen, Shizuka Uchida
    Computation.2023; 11(6): 105.     CrossRef
  • Genetic and Epigenetic Etiology of Inflammatory Bowel Disease: An Update
    Sara Jarmakiewicz-Czaja, Magdalena Zielińska, Aneta Sokal, Rafał Filip
    Genes.2022; 13(12): 2388.     CrossRef
  • Biological impact of mutually exclusive exon switching
    Su Datt Lam, M. Madan Babu, Jonathan Lees, Christine A. Orengo, Marco Punta
    PLOS Computational Biology.2021; 17(3): e1008708.     CrossRef
  • Relating the transcriptome and microbiome by paired terminal ileal Crohn disease
    Chenwen Cai, Sibo Zhu, Jinlu Tong, Tianrong Wang, Qi Feng, Yuqi Qiao, Jun Shen
    iScience.2021; 24(6): 102516.     CrossRef
  • Meta-Analysis of Expression Profiling Data Indicates Need for Combinatorial Biomarkers in Pediatric Ulcerative Colitis
    Xinxiu Li, Eun Jung Lee, Danuta R. Gawel, Sandra Lilja, Samuel Schäfer, Huan Zhang, Mikael Benson
    Journal of Immunology Research.2020; 2020: 1.     CrossRef
  • Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design
    Christopher J Tyler, Mauricio Guzman, Luke R Lundborg, Shaila Yeasmin, Tamara Perez-Jeldres, Andres Yarur, Brian Behm, Parambir S Dulai, Derek Patel, Giorgos Bamias, Jesús Rivera-Nieves
    Journal of Crohn's and Colitis.2020; 14(10): 1364.     CrossRef
  • TL1A primed dendritic cells activation exacerbated chronic murine colitis
    Fei Han, Jia Song, Wenxiu Jia, Mingyue Yang, Dong Wang, Hong Zhang, David Q. Shih, Stephan R. Targan, Xiaolan Zhang
    Life Sciences.2020; 262: 118220.     CrossRef
  • Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways
    Eden Ngah Den Low, Norfilza Mohd Mokhtar, Zhiqin Wong, Raja Affendi Raja Ali
    Journal of Crohn's and Colitis.2019; 13(6): 755.     CrossRef
  • A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia
    Norfilza Mohd Mokhtar, Khairul Najmi Muhammad Nawawi, Jaarvis Verasingam, Wong Zhiqin, Ismail Sagap, Zairul Azwan Mohd Azman, Luqman Mazlan, Hamzaini Abdul Hamid, Nur Yazmin Yaacob, Isa Mohamed Rose, Eden Low Ngah Den, Mah Suit Wan, Raja Affendi Raja Ali
    BMC Public Health.2019;[Epub]     CrossRef
  • 9,864 View
  • 124 Download
  • 11 Web of Science
  • 11 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP